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Abstract 
Wilson’s disease, SAPHO syndrome and Hereditary angioedema are three rare 
disorders characterized by a wide  spectrum of different clinical manifestations, 
which involve several organs and apparatus, making the diagnosis extremely 
difficult. In this study, the salivary proteome and peptidome of subjects affected 
by these pathologies has been investigated using mass spectrometry, through 
an integrated top-down and bottom-up platform, and compared with groups of 
healthy controls, with the aim to assess whether qualitative and quantitative 
variations of salivary proteins and peptides could be associated to the immune 
derangement distinctive of each disease and in order to have suggestions on 
potential specific salivary biomarkers.  
The analysis of the salivary proteome from patients affected by Wilson’s disease 
allowed to characterize new oxidized proteoforms of S100A8 and S100A9 and 
two fragments of the polymeric immunoglobulin receptor named ASVD and 
AVAD. Higher levels of these proteins and peptides observed in the patients 
are most likely connected to the oxidative stress, the activation of the 
inflammatory processes, and the hepatic damage caused by the altered copper 
transport and its subsequent accumulation in the organism, which is at the 
origin of the pathology. The observed increase of the level of α-defensins 2 and 
4 may give a contribution to the development of the disease by the 
improvement of the free copper.  
The proteome of patients affected by SAPHO syndrome revealed a significant 
decrease of cystatins, histatins, and aPRPs, which are involved in the protection 
against infections, suggesting a reduced ability of these subjects to contrast 
bacteria colonization, in particular P. acnes which is a possible trigger of this 
disease. In particular, the lower levels of histatins and the higher frequency of 
S100A12 observed in patients with respect to controls, may be connected with 
the dysregulation of the innate immunity and the neutrophil response typical of 
SAPHO syndrome. Cystatin SN abundance decrease correlated with the disease 
duration, suggesting its reduced production during the chronic phase of the 
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disease, while histatins showed positive correlation with serum levels of the C 
reactive protein. 
In saliva of Hereditary angioedema patients, the increased percentage of 
peptides generated by the proteolytic cleavage by metalloproteinases indicates 
the intense metalloproteinase activity possibly connected to the activation of 
inflammatory pathways. Interestingly, in consideration of the possible role of 
cystatin B in enhancing the production of nitric oxide, and the higher salivary 
levels measured in the patients, we suggest that cystatin B may give a 
contribution to the vasodilatation and the vasopermeability responsible for the 
oedema formation, which is the main feature of this pathology.  
In conclusion, the results obtained in these studies clearly highlighted that the 
salivary proteome showed some features specific of the three pathologies. Even 
though these results have been obtained in a small cohort of patients, due to the 
difficult recruitment of subjects affected by rare disorders, and need further 
validation by using orthogonal techniques, they strongly suggest that saliva, 
with easy and non-invasive collection characteristics, could be a biofluid 
suitable for diagnostic applications. 
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Introduction 
 Salivary Proteome 
Saliva is a clear body fluid hypotonic compared to plasma composed by more 
than 99% of water, that contains significant amounts of proteinaceous material 
(including enzymes such as amylase, lysozyme, lipase, acid phosphatase, 
lactoperoxidase, superoxide dismutase, etc.; various peptide hormones), 
glycoproteins (the main constituents of the mucosal secretions), lipid (hormones 
such as testosterone and progesterone) and inorganic ions such as sodium, 
chloride, potassium, calcium, magnesium, bicarbonate, phosphate. It is secreted 
by major (parotid, submandibular and sublingual) and minor (labial, palatine, 
buccal and lingual) salivary glands. According to viscosity of their secretions, 
that is dependent from the content of mucins and lipids, salivary glands can be 
clustered in serous (parotid), mucous (minor glands), and mixed (sublingual 
and submandibular). Under resting conditions, the contribution of parotid, 
submandibular and sublingual glands to saliva accounts for about 20%, 65% 
and 7%, respectively, and less than 10% derives from numerous minor glands. 
Saliva secretion follows circadian rhythms: the minimum flow rate is observed 
in the early morning, and the maximum of secretion is reached in the afternoon, 
when the parotid gland contribution accounts for more than 50% of the total 
secretion. The term “saliva” specifically refers to the salivary gland secretion, 
while “whole saliva” or “oral fluid” are both used to indicate the complex 
solution deriving also from the contribution of gingival crevicular fluid, and 
containing non-adherent bacteria and food residues (Edgar, 1992; Humphrey & 
Williamson, 2001). Saliva is essential for the preservation and the maintenance 
of the oral health, playing a wide range of different actions. This fluid is 
necessary to lubricate mouth tissues, forming a barrier against irritant elements, 
e.g. hydrolytic enzymes produced by plaque bacteria, and substances derived 
from smoking. Mucins, complex glycosylated proteins are the main lubricating 
components for their high viscosity, great elasticity, strong adherence and they 
participate to the formation of the acquired enamel pellicle that protect tooth 
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and also support speech, mastication and swallowing (Humphrey & 
Williamson, 2001; Messana, 2008a; Nieuw Amerongen, 2002). Some salivary 
elements, i.e. statherin, histatins, cystatins and salivary proline-rich proteins, 
regulate calcium homeostasis and mobilization, allowing the equilibrium 
between demineralization and remineralization necessary for the maintenance 
of the tooth integrity (Humphrey & Williamson, 2001; Messana, 2008a). Of great 
importance is saliva antibacterial activity, in which immunologic and 
nonimmunologic elements are involved: IgA, secreted by plasma cells; IgG and 
IgM, deriving from gingival crevicular fluid; glycoproteins, statherins, 
agglutinins, histidine-rich proteins, proline-rich peptides, mucins and enzymes 
secreted by salivary glands. Lactoferrin binds ferric ions that, consequently, are 
not available for microorganism nutrition, while, among the enzymes, 
lysozyme inhibits bacterial growth with the contribution of peroxidase that 
produces thiocynate, toxic for microorganisms, thus protecting tissues from 
oxidative stress caused by oral bacteria (Edgar, 1990; Edgar, 1992; Humphrey & 
Williamson, 2001). Also mucins give their contribution in the control of 
bacterial and fungal colonization promoting benign commensal flora growth. 
On the other hand, glycoproteins, statherin, agglutinins, histatins and salivary 
proline-rich proteins are involved in a “clumping” process that reduces bacteria 
ability to adhere and colonize oral tissues (Mandel, 1989; Humphrey & 
Williamson, 2001). Finally, but not less significant, is the role of saliva in 
nutrition giving its contribution to chewing, swallowing, digestion and taste 
perception (Humphrey & Williamson, 2001; Cabras, 2012a; Melis, 2015). Salty 
taste perception depends on saliva hypotonic nature and on gustin which is 
able to bind zinc ions (Humphrey & Williamson, 2001) while lubrication of the 
food bolus, promoted mainly by mucins, enhances the swallowing (Humphrey 
& Williamson, 2001; Hatton, 1985). 
The great variety of functions in which this body fluid is involved and its role in 
the health of the oral cavity highlights the importance of a proper salivation and 
saliva composition. In the last years many studies, allowed to identify several 
different components and to characterize various classes of proteins and 
peptides. Most of them are specific for the oral cavity and belong to four main 
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families (salivary proline-rich proteins, cystatins, histatins and statherin) while 
others are common to other organs and body fluids.  
Proline-rich proteins (PRPs) represent the major fraction of salivary proteins, 
more than 60% in weight of the total salivary proteome, and they can be 
classified in acidic (aPRPs), basic (bPRPs) and basic glycosylated (gPRPs) 
(Bennick, 1982). Acidic PRPs, secreted by parotid (70%) and submandibular and 
sublingual glands (30%), are encoded by two loci PRH-1 and PRH-2 localized 
on chromosome 12p13. PRH-1 codifies for PIF-s, Db-s and Pa, PRH-2 for PRP-1 
and PRP-2 proteins. The acidic character is due to several glutamic and aspartic 
acid residues located in the first 30 amino acids. All aPRPs show a pyroglutamic 
acid residue at the N-terminus and most of them present two phosphorylated 
serine residues at position 7 and 22 although low levels of mono-
phosphorylated, non-phosphorylated and three-phosphorylated (also on serine 
17) proteoforms can be detected in whole saliva. PRP-1, PRP-2, PIF-s and Db-s 
can be cleaved giving rise to a common peptide of 44 amino acids, named P-C 
peptide, and four truncated forms named PRP-3, PRP-4, PIF-f and Db-f. Instead 
Pa forms dimers through a disulfide bridge between cysteine 103 (Azen, 1987; 
Azen, 1988; Hay, 1994; Inzitari, 2005). Basic and glycosylated PRPs, secreted 
only by parotid glands, are the expression product of four loci: PRB1, 2, 3 and 4 
located near aPRP genes. Each locus includes at least 3 alleles: S, small; M, 
medium; L, large (Lyons, 1988a; Lyons, 1988b; Maeda, 1985a; Maeda, 1985b) 
and a further allele VL, very large, has been described for PRB1, PRB2 and PRB3 
(Lyons, 1988b; Azen, 1990). These alleles encode for pre-proproteins which, 
after peptide-signal removal, undergo extensive and complete proteolytic 
cleavages before secretion, thus only fragments of the proproteins can be 
detected in saliva. Proteins and peptides deriving from PRB1 proproteins are: 
II-2 peptide (from S, M, L alleles), P-E peptides and IB-6 protein (from S allele), 
Ps-1 protein (from M allele) and Ps-2 protein (from L allele). From  PRB2 
proproteins, IB-1, P-J, P-H, P-F peptides and IB-8a protein (from L allele) have 
been characterized while PRB3 and PRB4 proproteins give rise to glycosylated 
proteins and PRP4 proproteins also to P-D peptide (from S, M, L alleles). 
Moreover, P-J, P-F and IB-8a can be further cleaved during granule maturation 
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(Lyons, 1988a; Azen, 1993; Azen, 1996; Stubbs, 1998; Chan, 2001; Messana, 2004; 
Messana, 2008b; Cabras, 2009; Cabras, 2012b; Castagnola, 2012a; Manconi, 2015; 
Messana, 2015). Acidic PRPs play a role in modulating calcium ions 
homeostasis (Bennick, 1981), are absorbed in the hydroxyapatite forming the 
acquired enamel pellicle (Moreno, 1982; Bennick, 1983a) and could be involved 
in the bacterial colonization (Gibbons, 1991). On the other hand, basic PRPs 
bind tannins preventing their absorption and toxic effect on the gastro-intestinal 
tract (Bennick, 2002) and are involved in the perception of the bitter taste 
(Cabras, 2012a; Melis 2015). Glycosylated PRPs not only play lubricating actions 
(Hatton, 1985) but it has been also observed in vitro that bacteria can use their 
glycans as a substrate for their own metabolism and growth (Rudney, 2010). 
Salivary cystatins belong to the cystatin superfamily. They are encoded by 
CST1-5 genes, located on chromosome 20p11.21, and include three different 
families. Also called stefins, cystatin A and B are proteins ca. 100 amino acidic 
residues long, without disulfide bonds, and show cytoplasmic localization. 
Cystatin B has been observed in different body fluids and it has been detected 
in human saliva as S-modified derivatives: S-glutathionylated, S-cysteinylated 
and S-S dimeric form (Bobek, 1992; Dickinson, 2002; Cabras, 2012c). Salivary 
cystatins SN, SA and S (mainly secreted by the submandibular gland) (Shomers, 
1982) as well as cystatin C and cystatin D (this last one secreted by parotid 
gland) (Freije, 1991) belong to the family 2. They are constituted by ca. 120 
amino acids and present two intrachain disulfide bonds. Cystatin S can be 
mono-phosphorylated on serine 3 (S1) or di-phosphorylated on serine 1 and  
serine 3 (S2). All of them have been found in other body fluids like urine, tears 
and seminal plasma while cystatin C has a wider extracellular distribution 
(Abrahamson, 1986; Freije, 1991; Bobek, 1992; Dickinson, 2002). The third family 
of cystatins includes low-molecular-weight kininogen (LMWK), high-
molecular-weight kininogen (HMWK) and T-kininogens: single-chain 
glycoproteins with multiple disulfide bonds found in plasma and secretions 
(Dickinson, 2002). Cystatins are inhibitor of the cysteine proteinases, thus they 
protect the oral cavity from the proteolytic action of host, bacterial, viral and 
parasitic proteinases. Furthermore, they seem to play an antibacterial and 
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antiviral action not related with proteinase inhibitory activity. They also 
showed antifungal action and the ability to modulate the immune system 
(Bobek, 1992; Gu, 1995; Blankenvoorde, 1996; Abe, 1998; Hiltke, 1999; Baron, 
1999; Ruzindana-Umunyana, 2001; Dickinson, 2002; Magister, 2013; Lindh, 
2013). Salivary cystatins also participate to the mineralization of the tooth and 
to the formation of the acquired enamel pellicle (Bobek, 1992; Dickinson, 2002). 
Cystatin SN and marginally SA are also able to control lysosomial cathepsins 
implicated in the destruction of periodontal tissues (Bobek, 1992; Baron, 1999). 
Moreover, Cystatin SA has been implicated in the induction of cytokines by 
human gingival fibroblasts (Kato, 2000).  
Histatins are low molecular weight peptides, deriving their name from the high 
number of histidine residues on their structure, secreted both by major and 
minor salivary glands. Two genes, HIS1 and HIS2, localized on chromosome 
4q13, encode respectively for histatin 1 and histatin 3 that have a similar 
sequence. Before secretion, histatin 3 is exposed to an extensive proteolytic 
cleavage, leading the formation of histatin 6 (histatin3 1/25), histatin 5 (histatin3 
1/24) and other fragments. On the other hand, histatin 1 is not cleaved and is 
mostly found phosphorylated at serine 2;  minor tyrosine-sulfated derivatives 
have been also described (Oppenheim, 1988; Castagnola, 2004; Cabras, 2007; 
Messana, 2008a; Fabian, 2012; Cabras, 2014). Histatins show antifungal activity 
(Ruissen, 2001; Diaz, 2005), inhibitory effect on several oral bacteria (White, 
2009), stimulate wound healing (Oudhoff, 2010), and they are also involved in 
the formation of the enamel pellicle and in the protection of the tooth structure 
(Humprey, 2001; Li, 2004; Yin, 2006; Vitorino, 2007; Vitorino, 2008) Histatin-
derived peptides, like histatin 5, have been demonstrated to be active against 
various microbes (Oppenheim, 1999).  
Statherin is a small peptide of 43 amino acids codified by the STATH gene 
located on chromosome 4q13.3 (Sabatini, 1987). Secreted by parotid and 
submandibular glands (Schlesinger, 1977), it is di-phosphorylated on serine 2 
and serine 3, but also mono- and non-phosphorylated isoforms of this protein 
and a cycle-statherin can been observed in low quantities (Cabras, 2006; 
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Messana 2008a). Statherin has been demonstrated to play a key role in the oral 
calcium homeostasis, having high affinity for the hydroxyapatite, in the teeth 
mineralization and in the formation of the enamel pellicle, especially the 
cyclized form (Cabras, 2006; Schlesinger, 1977). Usually included in the bPRP 
family, the P-B peptide is encoded by PROL3 which is strictly close to the 
statherin gene, suggesting a functional relationship with this protein. However, 
its role has not been defined yet (Messana, 2008a; Isemura, 2000; Inzitari, 2006). 
Other proteins and peptides not specific of saliva are generally detected in this 
body fluid, i.e. defensins, thymosins, S100 proteins, α-amylases, albumin, 
agglutinin, carbonic anhydrase, peptide hormones and immunoglobulins. Some 
of these proteins, investigated in the present study, are described below. 
α-defensins, also named human neutrophil peptides, are basic peptides rich in 
tyrosine and cysteine residues, the latter forming three disulfide bonds. DEFA1, 
DEFA3 and DEFA4 genes, located in chromosome 8p23.1, encode for α-defensin 
1, 3 and 4 respectively, while α-defensin 2 derives from a proteolytic cleavage of 
the N-amino-terminal residue of α-defensin 1 or 3 (Valore, 1992). Detected in 
saliva, these four defensins derive mainly from the gingival crevicular fluid 
(Pisano, 2005) and in particular from neutrophils. They have antimicrobial 
activity and are involved in the regulation of the cell volume, cytokine 
production (Chaly, 2000; Lehrer, 2012), chemotaxis and inhibition of natural-
killer cells (Goebel, 2000). α-defensin 4, also called corticostatin, exhibits pro-
inflammatory effects through its anti-corticotropin property, which inhibits the 
production of cortisol (Singh, 1988).  
β-thymosins are ubiquitous polar peptides, firstly isolated from calf thymus 
(Klein, 1965), which are involved in the prevention of actin filament 
polymerization, induction of metalloproteinases, chemotaxis, angiogenesis; 
inhibition of inflammation and bone marrow stem cell proliferation. They have 
been also associated to cancer and metastasis formation (Huff, 2001; 
Hannappel, 2007; Hannappel, 2010). Thymosin β4, and β4 oxidized (encoded by 
TMSB4X gene clustered on chromosome Xp22.2) and β10 (encoded by TMSB10 
located on chromosome 2p11.2) have been detected in whole saliva; they mainly 
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derive from gingival crevicular fluid (Badamchian, 2007; Inzitari, 2009; 
Castagnola, 2011a). 
S100s are a family of low molecular weight acidic proteins with two distinct 
calcium ion binding domains. 25 proteins have been identified, among them 
S100A proteins are encoded by genes located on chromosome 1q21. They have 
no intrinsic catalytic activity but, after calcium binding, structural modifications 
allow them to bind and modulate the action of other proteins. S100 proteins, 
abundant in vertebrates but completely absent in invertebrates, are 
constitutively expressed in neutrophils, myeloid cells, platelets, osteoclasts and 
chondrocytes but can be induced and overexpressed in several cell types 
(macrophages, monocytes, keratinocytes, fibroblasts) in acute and chronic 
inflammatory, and oxidative stress conditions (Edgeworth, 1991; Vogl, 1999; 
Eckert, 2004; Carlsson, 2005; Sedaghat, 2008; Lim, 2008; Goyette, 2011). It has 
been demonstrated their involvement in a wide range of intracellular and 
extracellular functions: regulation of calcium homeostasis, cytoskeletal 
rearrangement, contraction and motility, cell growth and differentiation, 
membrane organization, arachidonic acid transport, chemotaxis, apoptosis, 
promotion of wound repair, protection against microbial proliferation, control 
of ROS formation, inflammation and protein phosphorylation and secretion 
(Ravasi, 2004; Santamaria-Kisiel, 2006; Lim, 2008; Sedaghat, 2008; Thorey, 2001; 
Donato, 2003). Their activity can be altered and regulated through formation of 
homodimers and heterodimers and by numerous post translational 
modifications: phosphorylation, methylation, acetylation and oxidation that can 
change their ability to bind ions or target proteins (Lim, 2008; Andrassy, 2006; 
Zimmer, 2003). In particular, S100A8 and S100A9 act as scavengers of ROS, 
protecting tissues from the excess of oxidant (Lim, 2008; McCormick, 2005; 
Harrison, 1999). Among them, S100A7, S100A8, S100A9, S100A11 and S100A12 
were already detected in human saliva (Castagnola, 2011a). 
Today, a great number of studies on the salivary proteome have provided an 
increasingly comprehension of the composition of this biological fluid and the 
wide spectrum of functions in which salivary proteins are involved has 
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stimulated research to fully understand their mechanisms of action, their 
reciprocal interaction and the relations with other components in the oral 
cavity. Moreover, the easy, rapid and noninvasive collection of saliva samples 
pushed, in the last years, many researchers to consider the possibility of using 
this biofluid for diagnostic and prognostic purposes, not only for oral diseases 
but also for systemic pathologies. Thus, several proteomic studies have been 
performed to evidence potential salivary biomarkers, and the research done 
during this PhD had this main goal. 
 Top-down and Bottom-up integrated platforms for proteomic 
analysis  
Proteomics studies on the complex human salivary proteome composition are 
mainly performed by the association of high-throughput separation methods 
with the different mass spectrometry techniques. Several proteomic platforms 
have been developed to achieve specific goals with the best results.  
Proteomic platforms can be classified in qualitative and quantitative (Nikolov, 
2012) as well as in top-down and bottom-up (Bogdanov, 2005). 
According to the purpose of the study, qualitative or quantitative platforms can 
be adopted. Qualitative analyses are carried out either to characterize the whole 
proteome and peptidome of a sample or to analyze specific protein classes, or 
post-translational modifications, or the typical set of proteins specifically 
expressed in cellular sub-compartments,  without considering their abundance. 
Conversely, quantitative platforms are employed to determine the amount of 
each protein component within and among different samples, as levels of 
proteins and/or their different isoforms can change under different 
physiological and pathological conditions.  
Top-down and bottom-up approaches differ in the protocol applied for the sample 
treatment (Fig.1). Top-down platforms analyze proteins and peptides in their 
naturally occurring form, giving particular attention to avoid, as much as 
possible, any sample alteration (Tipton, 2011). The bottom-up approach derives 
from the shot-gun strategies developed for the detection of DNA sequences in 
genomic studies and consists in the analysis of the sample digested by specific 
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enzymes, generally trypsin, which cleave proteins in correspondence of defined 
amino acidic residues. Tryptic peptides showing a primary sequence that is 
univocal for a specific protein (unique peptides) allow to deduce the protein 
presence within the original sample.  
 
Fig.1 Top-down and Bottom-up approaches.  
Both top-down and bottom-up analyses carried out by tandem mass spectrometry 
require previous separation steps, in order to reduce the high complexity of the 
mixture. Separation methods can be classified in: gel-based approaches, which 
can be applied for bottom-up analysis, such as the 2-dimensional gel 
electrophoresis (2-DE); or gel-free-based approaches, employed for top-down 
experiments, for example liquid chromatography.  
According to the temporal order between the separation step and the digestion 
process, bottom-up strategies can be further classified in break-then-sort and 
sort-then break (Han, 2008). In break-then-sort approaches, the digestion is 
carried out on the whole set of proteins present in the sample followed by high 
efficient chromatographic separations coupled to tandem mass spectrometry 
experiments. On the other hand, in sort-then break strategies, the proteome is 
submitted to the separation steps in order to select and then digest only specific 
proteins of interest further submitted to MS/MS spectrometry analyses. The 
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later approach is adopted, for example, in experiments centered on the 
phospho-proteome characterization or on the study of the less abundant 
proteins by enriched fraction preparation. 
Top-down mass spectrometry analyses of the human saliva acidic soluble 
fraction enable the simultaneous detection of all the soluble proteins and 
peptides in the sample (Castagnola, 2012b). High-resolution MS instruments 
allowed to obtain accurate structural information, as well as to identify and 
characterize different polymorphisms and several post-translational 
modifications, i.e. phosphorylation, N-terminal acetylation and oxidation 
(Messana, 2004; Inzitari, 2005; Inzitari, 2006; Messana, 2008b; Cabras, 2010; 
Cabras, 2012c; Castagnola, 2012b, Iavarone, 2013; Cabras, 2013). Of great 
interest is also the possibility to characterize the naturally occurring peptides 
generated in the sample by the action of –endo and exo-proteases (Amado, 
2010; Thomadaki, 2011). Moreover, the top-down approach allowed to establish 
the specific origin of the proteins (glandular, ductal or oral) and even to clarify 
when post-translational modifications and proteolytic cleavages occur along the 
secretory pathway (Messana, 2008b).  
Top-down proteomics allows label-free quantification of entire proteins, peptides 
and their different derivatives and fragments naturally present in the sample by 
a powerful label-free approach based on the measurement of the eXtracted Ion 
Current (XIC) peak area. This approach, avoiding the employment of labeled 
peptides, consents to perform quantification without any limitation on the 
number of the species under study (Castagnola, 2012b; Cabras, 2014). The 
relative percentages of different isoforms of the same protein in a sample can be 
calculated (Inzitari, 2005; Iavarone, 2013) and their diverse abundance, as well 
as the dissimilar patterns of protein fragmentation, can be compared in 
different samples and correlated to specific physiological states (Cabras, 2009; 
Morzel, 2012; Hardt, 2005b; Messana, 2015) or pathological conditions 
(Thomodaki, 2013; Cabras, 2010; Cabras, 2013).  
Despite the wide spectrum of applications, the top-down tandem mass 
spectrometry platform bears some drawbacks. In fact, this technique does not 
allow to characterize the intact structure of higher molecular weight or 
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glycosylated proteins, due to the complexity of MS/MS spectra, that cannot be 
automatically analyzed by available software (Meyer, 2011). 
Conversely, the bottom-up approach supported by data banks and bio-
informatics tools for automatic analysis of MS/MS data allows to characterize 
thousands of peptides in a single experiment. However, the enzymatic 
fragmentation preceding the analysis reflects on the inevitable loss of 
qualitative and quantitative information on the naturally occurring peptidome. 
In addition, post-translational modification may remain undetected by this 
approach, and determination of the abundance of different isoforms of the same 
protein within the sample may be not possible (Tipton 2011, Castagnola, 2012b; 
Messana, 2013; Cabras, 2014). 
On the basis of these considerations, the best solution to perform a deep 
characterization of the human salivary proteome and peptidome is the 
implementation of both top-down and bottom-up approaches, in order to take 
advantage of the two strategies and contemporaneously minimize their 
limitations (Cabras, 2014).  
 Wilson’s disease  
Wilson’s disease (WD) is an autosomal recessive genetic disorder of copper 
metabolism, characterized by a defective biliary excretion of copper and its 
failed incorporation into ceruloplasmin, a copper-protein with ferroxidase 
activity that normally binds 95% of blood copper (Hellman, 2002). The resulting 
excess of free copper in hepatocytes causes oxidative stress, apoptosis and 
hepatic damage. As a consequence, a massive amount of unbound copper is 
spilled into the blood and accumulated in other organs, such as brain, heart, 
kidney, and cornea, which in turn will be impaired (Ala, 2007). The pathology is 
connected to the activity of the transmembrane p-type ATPase called ATP7B. At 
low or normal copper level, the ATP7B transports copper into the trans Golgi 
compartment for its incorporation into ceruloplasmin, while at high level, 
copper is moved to be excreted with the bile (Fanni, 2005). Mutations in ATP7B 
block the transport of copper (Huster, 2003). In the European population, the 
modification H1069Q is the most common but over 350 different ATP7B 
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mutations have been identified, and are listed in the Wilson’s disease mutation 
database (http://www.wilsondisease.med.ualberta.ca/database.asp) (Bugbee 
2001). The majority of patients are heterozygous, and the distribution of the 
mutations depends on the population tested (Ala, 2007). The incidence of the 
disease is estimated from 1/30000 to 1/100000 with a carrier frequency of 1/90 
(Wu, 2015), although the incidence is varying in different populations, i.e. in 
Sardinian people is about 1/3000 live births (Gialluisi, 2013). Wilson’s disease is 
a progressive disorder with a broad spectrum of clinical manifestations: hepatic, 
neurological and psychiatric that may develop in variable way (Ala, 2007; 
Crisponi, 2012; Carta, 2012). The early diagnosis is crucial, as the disease can be 
lethal when untreated, and prevents neurological disability and liver cirrhosis 
(Gitlin, 2003). A unique diagnostic test is not available. In fact, the diagnosis, 
that is easy in patients with neurological symptoms but hard in individuals 
with liver deficiencies, is based on the evaluation of different features and on 
the recognition of typical symptoms, the later often non-specific, and confusing. 
Decreased serum ceruloplasmin, increased urinary copper excretion, elevated 
hepatic copper concentration and serum aminotransferases, and Kayser-
Fleischer rings on cornea are considered diagnostic biomarkers of the disease 
(Ala, 2007; Ferenci, 2003; Roberts, 2003). Nonetheless, 5-40% of patients exhibit 
normal ceruloplasmin levels (Steindl, 1997), the serum/urine copper levels can 
be equivocal, and aminotransferase activity cannot reflect the severity of liver 
injury (Ala, 2007). In addition, histochemical confirmation of the liver copper 
content, helpful in diagnosis, requires invasive analyses, and a negative result 
cannot exclude the pathology (Ferenci, 2005; Sini, 2013; Liggi, 2013). ATP7B 
mutation analysis is very advantageous, but systemic genetic testing is not 
routinely applied in clinical practice due to the many different mutations 
implicated. The need of novel and unequivocal diagnostic biomarkers has 
stimulated the research towards proteomics investigations on animals (Lee, 
2011; Simpson, 2004; Wilmarth, 2012), in vitro models (Roelofsen, 2004) and 
human serum (Park, 2009) of Wilson’s disease. These studies, based on bottom-
up proteomic platforms, highlighted altered levels of proteins involved in the 
oxidative stress, which is the typical feature of Wilson’s disease.  
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 SAPHO syndrome 
Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) syndrome is a 
rare and often unrecognized disorder characterized by cutaneous and 
musculoskeletal inflammations, which appear in variable combinations 
(Nguyen, 2012). SAPHO syndrome has been classified in the 
spondyloarthropathies (SpA) on the basis of clinicopathological features and 
similarity to psoriatic arthritis (Van Doornum, 2000). Recent evidences leads to 
consider this disorder within the spectrum of bone autoinflammatory diseases 
(Colina, 2010; Kastner, 2010). Although several studies investigated the origin of 
the disease and the relationship with mandibular osteomyelitis, the etiology, 
probably involving genetic, immunologic and infectious mechanisms, is still 
unknown (Mochizuki, 2012; Suei, 2003), The interaction between infectious 
agents (i.e. Propionibacterium acnes) and the immune system in a genetically 
predisposed subject may result in dysregulation of neutrophil responses and 
autoinflammation (Hurtado-Nedelec, 2008; Assman, 2011). First-line treatment 
is usually based on steroidal anti-inflammatory drugs (NSAIDs), systemic 
corticosteroids, bisphosphonates and synthetic disease-modifying anti-
rheumatic drugs (DMARDs), but there is no standard therapy for SAPHO 
syndrome. Biological drugs, particularly anti-tumor necrosis factor alpha (TNF-
α) and anti-interleukin-1 (IL-1) agents, have been successfully employed but 
usually reserved to resistant cases (Firinu, 2014b). Due to its rarity (estimated 
prevalence <1/10000), and features overlapping with other rheumatic and non-
rheumatic disorders, SAPHO syndrome represents a diagnostic challenge for 
clinicians (Nguyen, 2012). In particular, cutaneous manifestations may overlap 
with psoriasis or other neutrophilic dermatoses (Braun-Falco, 2011), and bone 
manifestations with SpA and infectious osteitis. To date, no reliable biomarkers 
have been available for this disease. Despite extensive bone and skin 
inflammation during exacerbations, the C reactive protein (CRP) and the 
erythrocyte sedimentation rate (ESR) are usually normal or only slightly 
elevated in less than one third of the cases. Moreover, routine laboratory means 
do not allow to detect and evaluate the low-grade inflammatory activity that 
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may persist also during remission (Colina, 2009). Therefore, it would be of 
extreme importance the identification of new laboratory biomarkers for the 
diagnosis of the disease and monitoring of its activity.  
 Hereditary angioedema 
Hereditary angioedema (HAE) is a rare autosomal dominant disease, which 
affect 1 out of 50000 individuals (Bafunno, 2014). Firstly described by Quincke 
in 1882 and fully documented by Osler in 1888 (Quincke, 1882; Osler, 1888), the 
disease is clinically characterized by recurrent episodes of nonpruritic acute 
swelling involving the face, the trunk as well as the extremities, the skin, the 
gastrointestinal mucosa and the upper respiratory tract, leading to airway 
obstruction and asphyxiation if not promptly treated (Frank, 1976; Davis, 2005; 
Zuraw, 2008; Bafunno, 2014).  
The disease is connected to mutations that can occur in SERPING1 gene or in 
FXII gene, which respectively encode for the C1 esterase inhibitor (C1-INH) and 
for the coagulation factor XII (FXII), also called Hageman factor. Alterations in 
SERPING1 gene have been detected since 90’s and nowadays an extremely 
large number of mutations are listed in a database created in 2005 by Kalmár 
(Kalmár, 2005; http://hae.enzim.hu/index.php). Alterations of this gene in 
HAE patients can determine low concentrations  of serum C1-INH (Donaldson, 
1963), or the production of a protein with defective inhibitor functions. These 
two different patterns were firstly documented by Rosen, who proposed to 
classify these patients as HAE type I and HAE type II, respectively (Rosen, 
1965; Rosen, 1971). Another type of HAE, characterized by normal C1-INH 
protein and absence of SERPING1 mutations, has been documented and 
initially named HAE type III (Binkley, 2000; Bork, 2000). Originally observed 
exclusively in women (Binkley, 2000; Bork, 2000) and correlated with high 
estrogen level conditions (i.e. pregnancy or use of exogenous estrogens) 
(Binkley, 2000; Bork 2003, Picone; 1010), this last form has been found recently 
also in male subjects (Bork, 2006; Bork, 2007; Martin, 2007; Vitrat-Hincky, 2010; 
Charignon, 2014; Moreno, 2015). Genetic studies allowed to associate HAE type 
III with mutations occurring in FXII gene (Dewald, 2006; Bork, 2011; Kiss, 2013).  
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The coagulation factor XII and the C1 esterase inhibitor are strictly connected. 
C1-INH is the main inhibitor of the classical pathway of the complement 
cascade and, in addition to its well-known ability to block the first component 
of the complement system C1 (Ratnoff, 1957; Ratnoff, 1969; Harpel, 1975), this 
protein is also able to inhibit some serine proteases acting in the kallikrein-kinin 
formation system and in the blood coagulation cascade, in particular FXII, 
which plays a central role in the activation of these pathways (Harpel, 1975; 
Schreiber, 1973a; Schreiber, 1973b; van der Graaf, 1983; de Agostini, 1984; Davis, 
1986; Salvesen, 1985). Thus, in HAE type I and II, low levels and defective 
functionality of C1-INH protein lead to an impaired inhibition of the 
coagulation factor XII. Furthermore, FXII gene mutations have been associated 
with the expression of proteins characterized by a more efficient activation 
(Dewald, 2006; Chicon, 2006; Bjӧrqvist, 2015), and different studies 
demonstrated increased prekallikrein activation in HAE patients (Shapira, 1982) 
and the presence of higher levels of the final product of the kallikrein-kinin 
pathway, the bradykinin peptide, in the region of the edema during acute 
attacks (Nussberger, 1998; Nussberger, 1999; Cugno, 2003). These evidences 
suggested that this peptide plays a main role in HAE as its overproduction 
leads to the increased vasodilatation, endothelial permeability and vascular 
leakage responsible for HAE subcutaneous and submucosal swelling (Fields, 
1983; Shoemaker, 1994; Dewald, 2006; Cichon, 2006). 
Although different genes are responsible for HAE disease, the common 
involvement of C1-INH and FXII in the kallikrein-kinin system formation 
pathway gives rise to similar clinical manifestations.  
A recent classification of different forms of angioedema proposed by Cicardi 
(Cicardi, 2014), which includes both hereditary and acquired typologies has 
been adopted in this study. HAE caused by mutations in SERPING1 and FXII 
genes are classified as C1-INH-HAE (which embraces both type I and type II) 
and FXII-HAE, respectively, while a third subgroup includes subjects with 
familial hereditary angioedema with unknown genetic mutation (U-HAE). All 
these inherited forms can be distinguished from a second group in which the 
pathology is acquired, causing C1-INH deficiency without family history (C1-
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INH-AAE) or it is triggered by treatment with inhibitors of the angiotensin-
converting-enzyme (ACEI-AAE) or else is generated by non-identified causes. 
The latter, is further divided in idiopathic histaminergic angioedema (Ih-AAE), 
in which the recurrent episodes of swelling can be blocked by continue 
histamine administration, and idiopathic non-histaminergic angioedema (InH-
AAE) which is resistant to histamine action (Cicardi, 2014).  
       
Fig.2 Classification of angioedema different forms. 
Different strategies have been developed to treat HAE, focused both on the 
control of acute swelling attacks when they manifest, and prevention of the 
number and the severity of further episodes by short and long term 
prophylaxis. Plasma purified C1-INH or the safer recombinant C1-INH 
(Ruconest®, Pharming Group and Salix Pharmaceuticals) are treatment of 
choice to contrast acute attacks, being able to replace the deficiency of the native 
protein, and thus mainly used for C1-INH-HAE. Moreover, a synthetic 
competitive antagonist of bradykinin for Bk2R receptor binding, Icatibant 
(Firazyr®, Jerini AG, Sydney, Australia) has been efficiently developed, both for 
C1-INH-HAE and FXII-HAE. A third option is the subcutaneous administration 
of Ecallantide (Kalbitor®, Dyax Corp., Cambridge, MA, USA), a recombinant 
protein which is able to inhibit kallikrein activity and thus bradykinin 
formation. For long-term cures, attenuated androgens (mainly Danazol and 
Stanozolol which increase hepatic C1-INH production) or tranexamic acid (that 
Angioedema
Hereditary
C1-INH-HAE
FXII-HAE
U-HAE
Acquired
C1-INH-AAE
ACEI-AAE
No identified 
causes
IH-AAE
InH-AAE
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blocks plasminogen proteolytic activity) are generally used. For U-HAE 
patients each of the previously mentioned therapies can be chosen, although an 
universal therapy is not yet available. Tranexamic acid is mainly employed for 
long-term prophylaxis of InH-AAE patients, although the response of the 
patients to the treatment is different, while In-AAE symptoms can be efficiently 
blocked by continue histamine administration. For ACEI-AAE patients, 
interruption of the ACE therapy is the first choice, but also bradykinin drugs 
can reduce the manifestations. On the other hand, plasma C1-INH and 
attenuated androgens are used for C1-INH-AAE. 
The similar manifestations of the pathology among these groups of patients and 
the unclear causes responsible for some forms of angioedema, require in-depth 
studies focalized to identify genetic or molecular differences which can be 
useful to clarify the mechanisms of the disease and to develop focused and 
efficient treatments. 
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Objectives of the study 
The main goal of this study was to assess whether the immune derangement 
observed in the three pathologies investigated could be associated to qualitative 
and quantitative variations of the salivary proteins and peptides in the patients 
with respect to control subjects to have suggestions on potential biomarkers 
selective for each condition.  
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Materials and methods 
 Materials 
All chemicals and reagents were of analytical grade and were purchased from 
Sigma Aldrich (St. Louis, MI), Merck (Darmstadt, Germany) and Bio-Rad 
(Hercules, CA). 
 Samples 
Study subjects 
The informed consent process was in agreement with the latest stipulations 
established by the Declaration of Helsinki. Ethics Committee approval was 
obtained for the study.  
Wilson’s disease 
Wilson’s disease patients were enrolled at the Hepato-Gastroenterology Service 
of the “Policlinico Universitario Monserrato”, Cagliari. The patients were 32 (42 
± 13 years old; 18 females, 14 males), the healthy control group comprised the 
same number of subjects (39 ± 14 years old; 19 females, 13 males. The diagnosis 
was based on the combination of several criteria: clinical symptoms, Kayser-
Fleisher ring, and laboratory tests. Based on clinical manifestations the patients 
were classified as hepatic (N = 23), hepatic/neurologic (N = 4), 
hepatic/psychiatric (N = 1), hepatic/neurologic/ psychiatric (N = 4). Diagnosis 
was confirmed by serum ceruloplasmin, total serum copper, cupruria baseline, 
hepatic parenchymal copper concentration following hepatic biopsy. 
Histological evaluation of grading and staging of liver fibrosis, and molecular 
biology analysis of the ATP7B gene mutations were also carried out. 
SAPHO syndrome 
10 SAPHO patients (38.0 ± 11.1 years old) with a protracted disease course, 
fulfilling criteria of Benhamou (Benhamou, 1988) were enrolled at the Internal 
Medicine and Immunology outpatients clinic of Cagliari University. 28 healthy 
females (33.5 ± 10.3 years old) were enrolled as controls.  
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Demographics, treatments and status of the disease were collected for SAPHO 
patients at the time of the study and they are listed in Table 1. 
Table 1. 
Pt  
# 
Disease 
duration 
(Years) 
Historical disease status 
Current 
treatment 
Current disease 
status 
Skin Bone Skin 
Bone 
(Site/s) 
1 27 
Hidradenitis 
suppurativa, 
psoriasis 
Sternal hyperostosis, 
Sspondylodiscitis 
Biological 
drug 
(ADAa) 
REMb 
ACTc 
(SCd) 
Partial remission 
2 8 Psoriasis 
Sternocostoclavicular 
osteitis, hyperostosis 
NSAIDse 
REM 
ACT  
(SC) 
Partial remission 
3 16 
Palmoplantar 
pustulosis 
Sternocostoclavicular 
hyperostosis and osteitis, 
zigomatic and parietal 
bone, multiple foci of 
spondylodiscitis 
Biological 
drug 
(ADA) 
ACT 
ACT  
(SC. SIf, 
Spine) 
No remission 
4 7 
Palmoplantar 
pustulosis 
Sacroiliitis, 
sternoclavicular 
hyperostosis 
Biological 
drug 
(ADA) 
REM 
ACT  
(SC, SI) 
Partial remission 
5 4 
Palmoplantar 
pustulosis 
Sternoclavicular osteitis 
Biological 
drug 
(ADA) 
REM 
ACT  
(Jaw, 
SC) 
Partial remission 
6 7 
Palmoplantar 
pustulosis 
Arthritis, synovitis, 
sternocostal hyperostosis, 
femur osteitis 
Biological 
drug 
(ADA) 
REM 
REM 
(None) 
Remission 
7 3 
Palmoplantar 
pustulosis 
Sacroiliitis, 
sternocostoclavicular 
osteitis 
Biological 
drug 
(ADA) 
REM 
ACT  
(SC) 
Partial remission 
8 2.5 None 
Sacroiliitis, 
sternoclavicular 
hyperostosis,  
clavicular edema 
Biological 
drug 
(ADA) 
- 
REM 
(None) 
Remission 
9 23 
Palmoplantar 
pustulosis 
Sternocostoclavicular 
hyperostosis and osteitis, 
sacroiliitis, femur osteitis 
NSAIDs 
ACT 
ACT  
(SC, SI) 
No remission 
10 10 Severe acne 
Arthritis (elbow, knee), 
sternocostoclavicular 
hyperostosis and osteitis 
Biological 
drug 
(ADA) 
REM 
REM 
(None) 
Remission 
aAdalimumab; bRemission; cActive; dSternocostal or sternoclavicular; eNon steroideal anti-
inflammatory drugs; fSacroiliitis. 
Microbiological cultures, performed on skin pustules from 7 patients, synovial 
fluid from 2 patients, and bone biopsy from 1 patient (#5) yielded negative 
results for P. acnes or other pathogens. All patients presented bone involvement 
with sternoclavicular osteitis and/or hyperostosis, 4/10 with sacroileitis and 
2/10 with spondylodiscitis. Skin involvement was observed in 9/10 patients: 
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palmo-plantar pustulosis in 6/9, psoriasis vulgaris in 2/9, and severe acne in 
one patient. Patient #8 was the one without cutaneous manifestations, whereas 
bone manifestations were similar to those observed in the others. Mean disease 
duration was 10.8 years ± 8.5 (SD) and patient #8 had the lowest (2.5 years). 
Blood samples with lithium heparin were also collected from SAPHO patients 
in the same day of saliva collection. The main clinical and laboratory findings 
are summarized in Table 2. 
Table 2. Clinical, laboratory and imaging findings of each SAPHO patient at 
the time of the study. 
Pt # 
Blood 
TH-17a 
Blood
TH-1b 
TH-1/TH-17 
Neutrophilia 
WBCc cells/mm3 
Neud cells/mm3 
Serum 
CRPe 
Serum 
ESRf 
1 
H 
2.91 
17.97 0.19 
N 
N 
0.39 
H 
32 
4900 
2470 
2 
N 
0.13 
4.55 0.13 
N 
N 
0.10 
N 
11 
8000 
4560 
3 
H 
3.05 
12.31 0.00 
N 
N 
0.47 
N 
10 
7200 
3900 
4 
H 
3.07 
25.19 0.24 
N 
N 
0.11 
H 
33 
 
8300 
3194 
5 
H 
2.77 
9.85 0.32 
N 
N 
0.4 
N 
18 
9400 
5640 
6 
H 
2.86 
21.29 0.10 
N 
N 
0.5 
N 
9 
10500 
6300 
7 
H 
2.1 
20.00 0.00 
N 
N 
0.24 
N 
30 
9700 
6200 
8 nd nd nd 
N 
H 
1.8 
H 
40 
7800 
3300 
9 nd nd nd 
N 
N 
0.2 
H 
55 
6200 
3521 
10 nd nd nd 
N 
H 
1.9 
N 
19 
11430 
5270 
a% TH-17 lymphocytes = CD4 + IL17 + Lymphocytes (normal range: 0.04-1.88%); b% TH-1 
lymphocytes; cTotal white cells (normal range: 4000 – 11.200/μl); dNeutrophils (normal 
range: 1800 - 7500/μl); eC reactive protein (normal range: 0-0.5); fErythrocyte sedimentation 
rate (normal range: <30); H: value higher than normal; N: normal value; nd: not determined. 
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Blood lymphocyte subsets defined as “TH-1” (CD4 + IFNγ+), “TH17” (CD4 + 
IFNγ- IL-17+), “TH1/TH17” (CD4 + IFNγ+ IL-17+) were defined by analysis of 
intracellular cytokine production using flow-cytometry, using a protocol 
previously described (Firinu, 2014a). White blood cell (WBC) counts, serum 
CRP and ESR were determined by routine methods. WBC count (mean 
8343/mm3 ± 1980 SD) was normal in all patients, CRP (mean 0.61 mg dl-1 ± 0.66) 
was above normal range in 2 patients, and ESR (24 mm h-1 ± 16.8 SD) in 4 
patients, but both were not related to disease activity status.  
Hereditary and idiopathic non-histaminergic angioedema  
A total of 37 patients affected by angioedema were recruited at the Unit of 
Internal Medicine, Allergy and Clinical Immunology of Cagliari University. On 
the basis of genetic analysis and familial information, patients were clustered 
into three subgroups:  C1-INH-HAE (6 men and 8 women, 49.1 ± 17.3 years old, 
mutation of SERPING1 gene),  FXII-HAE (1 male and 10 females, 37.82 ± 11.31 
years old, mutation of FXII gene), InH-AAE (5 men and 7 women, 41.4 ± 14.3 
years old, no mutations of SERPING1 and FXII genes). As regards InH-AAE 
patients, no heredity of the pathology was documented and any positive effect 
was observed after histamine treatment, thus they were not classified as U-HAE 
or IH-AAE. 12 out of 14 patients of the C1-INH-HAE group  were analyzed in 
the absence of symptoms (basal phase), one during an acute attack of 
angioedema (acute phase) and one in both conditions. 9 out of the 11 patients 
belonging to the FXII-HAE group were examined in basal phase, 1 in acute 
phase and 1 in both conditions. All the 12 InH-AAE patients were analyzed in 
basal phase. 31 healthy individuals (9 males and 22 females, 41.8 ± 13.0 years 
old) were enrolled as control group. 
Salivary sample collection 
Unstimulated whole saliva was collected according to a standardized protocol 
from patients and healthy controls using a soft plastic aspirator and transferred 
to a plastic tube in an ice bath. Donors did not eat or drink at least 2 h before the 
collection, which was established between 10.00 a.m. and 12.00 p.m. 
Immediately after collection, each salivary sample was diluted in 1:1 v/v ratio 
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with a 0.2% solution of 2,2,2-trifluoroacetic acid (TFA). Then the solution was 
centrifuged at 10000g for 10 min at 4°C (for Wilson’s disease study) and at 
20000g for 15 min at 4°C (for SAPHO syndrome and angioedema studies). The 
acidic supernatant was separated from the precipitate and either immediately 
analyzed by HPLC-ESI-MS apparatus (100 µl, corresponding to 50 µl of saliva) 
or stored at -80°C until low-resolution HPLC-ESI-IT-MS analysis. Also 
precipitates were stored at -80°C.  
 Experimental methods 
Low-resolution HPLC-ESI-IT-MS experiments 
Low-resolution reversed phase (RP)-HPLC-ESI-MS analysis of the acidic 
soluble fraction of whole saliva was carried out by a Surveyor HPLC system 
connected by a T splitter to a diode-array detector, and to a LCQ Advantage 
mass spectrometer (ThermoFisher Scientific San Jose, CA). The mass 
spectrometer was equipped with an electrospray ionization source (ESI) and an 
ion trap (IT). The chromatographic column was a reversed phase Vydac 
(Hesperia, CA, USA) C8 column with 5 µm particle diameter (150 x 2.1 mm). 
The chromatographic separation was carried out using eluent A (0.056% TFA 
acidic solution) and eluent B (acetonitrile/water 80:20 with 0.05% TFA). The 
gradient applied for the analysis of saliva was linear from 0 to 55% of B in 40 
min, and from 55% to 100% of B in 10 min, at a flow rate of 0.3 ml min-1. The T 
splitter addressed a flow-rate of 0.2 ml min-1 toward the diode array detector 
and 0.1 ml min-1 towards the ESI source. During the first 5 minutes of the 
analysis the eluate was not directed to the mass spectrometer to avoid that the 
high salt concentration could damage the instrument. The photodiode array 
detector was set at 214 and 276 nm. Mass spectra were collected every 3 ms in 
the m/z range 300-2000 in positive ion mode. The MS spray voltage was 5.0 kV, 
and the capillary temperature was 260 °C. MS resolution was 6000. 
Experimental mass values of each protein and peptide was obtained using the 
MagTran 1.0 software (Zhang, 1998) which automatically performs the 
deconvolution of the average ESI-MS spectra. The experimental values were 
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compared with the theoretical masses of the proteins registered at the Swiss-
Prot Data Bank (http:/us.expasy.org/tools). 
Enriched fraction preparation of S100A8 and S100A9 oxidized proteoforms 
from WD saliva samples and trypsin digestion 
Enriched fractions of S100A8 and S100A9 oxidized proteoforms previously 
uncharacterized were obtained by preparative RP-HPLC (Dionex Ultimate 3000 
instrument, ThermoFisher Scientific, Sunnyvale CA) of pools of Wilson’s 
disease saliva samples. The chromatographic column was a reversed phase 
Vydac (Hesperia, CA) C8 column with 5 µm particle diameter (250 x 10 mm). 
The solutions used for preparative RP-HPLC were the same utilized for 
analytical low-resolution HPLC-ESI-MS experiments. The gradient was linear 
from 0 to 60% B in 40 min and from 60 to 100% B in 5 min, with a flow rate of 
2.8 ml min-1. Four fractions corresponding to peaks eluting between 39 and 44 
min were collected separately and lyophilized. Each fraction was solubilized in 
100 µl of ultrapure H2O, and 1/3 of the solution was acidified with 0.2% TFA 
(1:1 v/v ratio) to be checked by low-resolution HPLC-ESI-MS. The remaining 
sample was submitted to digestion using the kit “Trypsin Singles Proteomic 
Grade” (Sigma-Aldrich) according to the manufacturer’s instructions. Digestion 
was stopped after 12 h by acidification with 0.1% TFA (final concentration), and 
the solution stored at -80 °C until the analysis by high-resolution HPLC-ESI-MS.  
High-resolution HPLC-ESI-MS/MS experiments 
High-resolution HPLC-ESI-MS/MS experiments were carried out on whole 
saliva samples and tryptic digests of enriched fractions from Wilson’s disease 
patients, with the aim to characterize S100A8 and S100A9 oxidized proteoforms 
and two fragments of the polymeric immunoglobulin receptor (pIgR). The 
instrument was an Ultimate 3000 Micro HPLC apparatus (ThermoFisher 
Scientific, Sunnyvale, CA) equipped with a FLM-3000-Flow manager module 
coupled to LTQ Orbitrap XL apparatus (ThermoFisher Scientific). The columns 
were a Zorbax 300SB-C8 column (3.5 µm particle diameter; 1.0 x 150 mm) for 
the top-down analysis, and a Zorbax 300SB-C18 column (5 µm particle diameter; 
1.0 x 150 mm) for the bottom-up. Eluents were: (eluent A) 0.056% (v/v) aqueous 
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TFA, and (eluent B) 0.05% (v/v) TFA in acetonitrile-water 80/20. For both top-
down and bottom-up analyses the gradient was: 0–2 min 5% B, 2-40 min from 5% 
to 55% B (linear), 41-43 min from 55% to 100% B, at a flow rate of 80 µL/min. 
MS and MS/MS spectra were collected in positive mode using the lock mass for 
internal mass calibration (polydimethyl cyclosiloxane, 445.1200 m/z) with the 
resolution of 60000 and 30000, respectively. The m/z range was from 600 to 2000 
in the top-down experiments, from 300 to 2000 in the bottom-up experiments. 
Tuning parameters: capillary temperature was 250 °C, and the source voltage of 
4.0 kV, capillary voltage and tube lens voltage were 37 V, and 150 V in the top-
down; 48 V and 150 V in the bottom-up experiments. In data dependent 
acquisition mode the three most abundant ions were selected and fragmented 
by using collision-induced dissociation (CID, 35% normalized collision energy 
for 30 ms, isolation width of 6-10 m/z, activation q of 0.25. The inject volume 
was 20 μl.  
Data were generated by Xcalibur 2.2 SP1.48 (Thermo Fisher Scientific) using 
default parameters of the Xtract program for the deconvolution. MS/MS data 
were analyzed by the Proteome Discoverer 1.2 program, based on Sequest 
cluster as a search engine (University of Washington, licensed to Thermo 
Electron Corp., San Jose, CA) against Swiss-Prot human proteome (September, 
2014 released; Swiss Prot human complete.fasta; 47622 non-redundant protein 
sequences). For peptide matching the limits were Xcorr scores greater than 1.5 
for singly charged ions, 2.0 and 2.5 for doubly and triply charged ions, 
respectively. Furthermore, the cleavage specificity was set to trypsin with two 
missed cleavages in the bottom-up analysis. Precursor mass search tolerance was 
10 ppm and fragment mass tolerance 0.8 Da. Target FDR was 0.01 (strict), 0.05 
(relaxed). The following modifications were searched: phosphorylation, 
acetylation, oxidation of methionine and tryptophan residues, as well as 
oxidative cysteine modifications, such as glutathionylation, cysteinylation, 
nitrosylation, sulfonic, sulfinic, and sulfenic acid. Peptide sequences and sites of 
covalent modifications were also validated by manual inspection of the 
experimental fragmentation spectra against the theoretical ones generated by 
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MS-Product software available at the ProteinProspector website 
(http://prospector.ucsf.edu/prospector/msh-ome.htm). 
Fractionation of the acidic soluble fraction of salivary proteins by 
ultrafiltration 
200 μl of the acidic soluble fraction of saliva were lyophilized, resuspended in 
100 μl of 5% acetonitrile/0.1% formic acid and then centrifuged at 10000g and 
20°C for 15 minutes using centrifugal filter units with a 50 kDa molecular 
weight cut-off (MWCO) (Vivaspin, Sartorius stedim biotech). Samples were 
stored at -80 °C until nano-HPLC-ESI-MS and MS/MS analyses. 
Filter aided sample preparation (FASP) 
Insoluble fractions obtained after whole saliva acidification and centrifugation 
were resuspended in 250μL of a urea/tiourea 2M 1% CHAPS buffer, sonicated 
for 1 minute (with an alternate cycle of 1 second of pause every 10 seconds) and 
then centrifuged at 10000g for 10 minutes at room temperature. For each sample 
total protein quantification was carried out using the RC-DC assay and 100 μg 
of protein were subjected to an endoProteoFASP (filter aided sample 
preparation) approach, which consists in the in-solution tryptic digestion of the 
sample and allows to obtain peptides for bottom-up LC-MS analysis. 30 μg of the 
tryptic digest was then loaded in a PierceTM C18 Spin Column (ThermoFisher) 
for the salts elimination. The eluate was dried in a Speed Vac, re-suspended in a 
5% acetonitrile/0.1% formic acid solution, sonicated for 3 minutes and finally 
centrifuged at 15000g for 3 minutes at room temperature. Samples were stored 
at -80 °C until nano-HPLC-ESI-MS and MS/MS analyses. 
Nano-HPLC-ESI-MS and MS/MS experiments 
Nano-HPLC-ESI-MS and MS/MS experiments were performed on the tryptic 
digests of the acidic insoluble fractions after FASP protocol and on the low-
molecular weight acidic soluble fraction (MW < 50 kDa). The eluting peptides 
were analyzed using an LXQ linear ion trap mass spectrometer. The 
chromatographic separation was carried out using eluent A (5% 
acetonitrile/0.1% TFA) and eluent B (acetonitrile/water 90:10 with 0.1% formic 
acid). The gradient employed was linear from 0% to 5% of eluent B in 10 
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minutes, from 5% to 40% of eluent B in 35 minutes, from 40% to 60% of eluent B 
in 10 minutes and finally from 60% to 90% of eluent B in other 10 minutes. The 
flow rate was 0.3 ml min-1. The first 10 minutes of the analysis were set up for 
the loop washing. LXQ settings were as follows: spray voltage, 1.8 kV; 1 
microscan for MS scans at maximum inject time 10 ms with mass range 400–
1650 m/z, 3 microscans for MS/MS at maximum inject time 100 ms with 
automatic mass range. The LXQ was operated in a data-dependent mode to 
execute top5, corresponding to one MS scan for precursor ions followed by four 
data-dependent MS/MS scans for precursor ions above a threshold ion count of 
450 with normalized collision energy value of 35%. Charge state screening was 
enabled to reject unassigned and 4+ charge states. Mass spectrometer was set to 
alternate during the entire experiment 10 μs of MS analysis and 10 μs of 
MS/MS analysis and to repeat this sequence for the three most abundant ions 
identified. Each sample was analyzed in duplicate. MS/MS data by bottom-up 
analyses were processed on Mascot software, while MS/MS data obtained by 
top-down analyses were processed on BioworksBrowser v3.0 (Thermo Fisher 
Scientific). DTA files were generated from LC-MS/MS raw files with the 
following options: precursor ion tolerance 1.5 Da, group scan 1, minimum 
group count 1, minimum ion count 20, and filtering through charge state 
analysis. The generated DTA files were searched against SwissProt protein 
database (March 2013) for Homo sapiens and its reversed-sequence version. 
Search on data obtained by bottom-up analysis of the insoluble fractions was 
prformed according the following criteria: enzyme, trypsin (KR/P); full 
enzymatic cleavage; missed cleavage sites, 2; peptide tolerance, 2.0 Da; 
fragment ions tolerance, 1.0 Da; variable modifications, carbamidomethylation 
(+57Da), methionine oxidation (+16Da), STY phosphorylation (+80Da); 
modifications per peptide, 3. The search result was filtered with Xcorr versus 
charge state (Xcorr of 1.5, 2.0 and 2.5 for +1, +2, +3 charges, respectively) and 
delta CN 0.08. Only proteins identified by at least two unique peptides and 
found in at least two different subjects were considered confident. Search on 
data obtained by top-down analyses of the soluble fractions was carried out with 
the same criteria, but excluding enzymatic cleavages and 
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carbamidomethylation and results were filtered with Xcorr versus charge state 
(Xcorr of 1.5, 2.0 and 3.0 for +1, +2, +3 charges, respectively).  
Bioinformatic analyses  
The open source software platform Cytoscape_v3.2.1 (http://www.cytoscape. 
org/) and the additional plugins ClueGO (http://apps.cytoscape.org/apps/cl 
uego) and CluePedia (http://apps.cytoscape.org/apps/cluepedia ) were used 
in order to visualize the interaction networks among the genes encoding 
proteins identified with confidence, and the biological pathways in which they 
are involved. In order to visualize only the most significant pathways, only 
pathways represented by at least 3 genes and accounting for at least the 3% of 
the total genes were selected. 
Prediction of proteases naturally acting in saliva 
The peptides naturally present in the acidic soluble fractions of saliva were 
analyzed by the Proteasix software to perform the in silico prediction of the 
proteases present in the oral cavity responsible for their generation. A database 
containing the association between proteases and cleavage sites (CS) allows to 
have suggestions on the most probable proteases responsible for the generation 
of the peptide.  
 Quantification 
Top-down proteomics experiments 
Intact protein quantification by low resolution HPLC-ESI-MS  
Proteins and peptides, previously identified and characterized in human saliva 
in our laboratory (Castagnola, 2004; Inzitari, 2005; Messana, 2008b; Cabras, 
2010; Castagnola, 2011a; Castagnola, 2012a, Castagnola, 2013), were quantified 
by the XIC procedure performed on low-resolution reversed phase (RP)-HPLC-
ESI-MS chromatograms. The typical low-resolution HPLC-ESI-MS total ion 
current (TIC) profile of the acidic soluble fraction of saliva from an healthy 
adult subject is shown in Fig.3. The elution ranges of the main classes of 
proteins and peptides, which are usually detected in saliva, are evidenced. 
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Fig.3
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Under our experimental conditions β-thymosins 4 and 10, basic PRPs, and 
histatins 3, 5 and 6 elute in the initial region of the chromatogram followed by 
histatin 1, acidic PRPs and α-defensins 1-3. In the central region, α-defensin 4, 
statherin and P-B peptide can be detected and afterwards cystatins and S100A7. 
Finally, in the last part of the chromatogram amylase and the other S100s 
proteins elute. To extract the XIC peaks, selected multiply-charged ions 
generated by the proteins/peptides at the electrospray ionization source  were 
searched in the chromatographic profile. The area of the XIC peaks is 
proportional to the protein concentration under constant analytical conditions, 
allowing to perform relative quantification of the same protein in different 
samples (Ong, 2005; Messana, 2008a). The m/z values selected to quantify 
proteins and peptides were chosen by excluding values in common with other 
closely eluting proteins (±0.5 m/z). The estimated percentage error of the XIC 
procedure was <8%. XIC peaks were considered when the signal to noise ratio 
was at least 5. Table 3 reports the Swiss-prot codes, the elution times, the 
experimental and theoretical average (low-resolution) and monoisotopic (high-
resolution) mass values (Mav., Mmonois.), and the multiply-charged ions 
utilized to selectively extract the ion current peaks used to quantify 
proteins/peptides and their derivatives. Basic proline-rich proteins were not 
evaluated due to their high variability linked to the physiological status 
(Cabras, 2009; Cabras, 2012a). 
Table 3. Proteins and peptides investigated: Swiss-prot code, elution time, 
experimental (exp.) and theoretical (th.) average and monoisotopic mass values 
(Mav., Mmonois.) and multiply charged ions used for XIC quantification are 
reported. 
Protein 
(Swiss-Prot code) 
El. time 
(min) 
Exp. Mav.   
(Th. Mav.) 
Da 
Multiply-charged ions 
selected for the XIC 
procedures  (m/z(charge)) 
Exp. Mmonois. 
(Th. Mmonois.) 
Da 
Histatin 1  
(P15515) 
23.3-23.8 
4928.2 ± 0.5  
(4928.2) 
1644.1(+3) 1233.5(+4) 
4925.22 ± 0.08 
(4925.200) 
Non-phosphorylated 
Histatin 1  
(P15515) 
23.4-23.8 
4848.2 ± 0.5  
(4848.2) 
1617.4(+3)  1213.5(+4) 
4846.25 ± 0.08 
(4846.233) 
Histatin 3   
(P15516) 
17.6-17.9 
4062.2 ± 0.4  
(4062.4) 
1355.1(+3) 1016.6(+4) 
4059.88 ± 0.07 
(4059.979) 
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Histatin 5  
(P15516) 
14.2-14.7 
3036.5 ± 0.3  
(3036.3) 
1013.2(+3) 760.1(+4) 
3034.53 ± 0.06 
(3034.522) 
Histatin 6  
(P15516) 
14.0-14.4 
3192.4 ± 0.3  
(3192.5) 
1065.1(+3) 799.1(+4) 
3190.63 ± 0.06 
(3190.623) 
Statherin 2Pa 
(P02808) 
28.9-29.5 
5380.0 ± 0.5 
(5379.7) 
1794.2(+3) 1345.9(+4) 
1076.9(+5) 
5376.5 ± 0.1 
(5376.450) 
P-B peptide 
(P02814) 
29.7-30.6 
5792.9 ± 0.5 
(5792.7) 
1932.0(+3) 1449.2(+4) 
1159.6(+5) 
5789.1 ± 0.1 
(5789.036) 
PRP-1 typeb 2P  
(P02810) 
22.9-23.6 
15515 ± 2  
(15514-
15515) 
1293.9(+12) 1194.4(+13) 
1035.3(+15) 970.7(+16) 
913.6(+17) 
15505.4 ± 0.2 
(15505.24-
15506.22) 
PRP-3 typec 2P  
(P02810) 
23.3-24.2 
11161 ± 1  
(11161-
11162) 
1595.5(+7) 1396.2(+8) 
1015.7(+11) 931.1(+12) 
859.6(+13) 
11155.1 ± 0.2 
(11155.08-
11156.06) 
P-C peptide   
(P02810) 
13.6-14.5 
4370.9 ± 0.4  
(4370.8) 
1457.9(+3) 1093.7(+4) 
4368.19 ± 0.07 
(4368.183) 
Cystatin S  
(P01036) 
37.4-38.2 
14186 ± 2  
(14185.8 ) 
1774.3(+8) 1577.2(+9) 
1419.6(+10) 1290.6(+11) 
1183.2(+12) 1092.2(+13) 
1014.3(+14) 
14176.8 ± 0.2 
(14175.81) 
Cystatin S 1P  (S1) 
(P01036) 
37.7-38.4 
14266 ± 2  
(14265.8 ) 
1784.3(+8) 1586.1(+9) 
1427.6(+10) 1297.9(+11) 
1189.8(+12) 1098.4(+13) 
1020.0(+14) 
14255.6 ± 0.2 
(14255.77) 
Cystatin S 2P (S2) 
(P01036) 
37.8-38.4 
14346 ± 2  
(14345.8 ) 
1794.3(+8) 1595.0(+9) 
1435.6(+10) 1305.2(+11) 
1196.5(+12) 1104.5(+13) 
1025.7(+14) 
14335.7 ± 0.2 
(14335.74) 
Cystatin SN  
(P01037) 
35.8-36.4 
14312 ± 2  
(14313.1) 
1790.0(+8) 1591.2(+9) 
1432.2(+10) 1302.1(+11) 
1193.7(+12) 1101.9(+13) 
1023.3(+14) 
14303.1 ± 0.2 
(14303.09) 
Cystatin SA  
(P09228) 
38.7-39.4 
14347 ± 2  
(14346.1 ) 
1794.4(+8) 1595.1(+9) 
1435.7(+10) 1305.3(+11) 
1196.6(+12) 1104.6(+13) 
1025.8(+14) 
14337.1 ± 0.2 
(14337.01) 
Cystatin A  
(P01040) 
31.3-32.1 
11006 ± 2 
(11006.5) 
1835.4(+6) 1573.4(+7) 
1376.8(+8) 1223.9(+9) 
1101.7(+10) 1001.6(+11) 
10999.7 ± 0.2 
(10999.66) 
Cystatin B-SSddimer 
(P04080) 
33.6-34.4 
22362 ± 3 
(22361.2) 
1864.4(+12) 1721.1(+13) 
1598.2(+14) 1491.8(+15) 
1398.6(+16) 1316.4(+17) 
1243.3(+18) 1177.9(+19) 
1119.0(+20) 1065.8(+21) 
1017.4(+22) 973.2(+23) 
nd 
Cystatin B-SSGe 
(P04080) 
32.5-33.1 
11487 ± 2 
(11486.7) 
1915.5(+6) 1642.0(+7) 
1436.9(+8) 1277.3(+9) 
1149.7(+10) 1045.3(+11) 
11479.6 ± 0.2 
(11479.68) 
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Cystatin B–SSCf 
(P04080) 
32.6-33.2 
11301 ± 2 
(11300.7) 
1884.5(+6) 1615.4(+7) 
1413.6(+8) 1256.6(+9) 
1131.1(+10) 1028.3(+11) 
11294.6 ± 0.2 
(11294.613) 
Cystatin C  
(P01034) 
38.2-38.9 
13343 ± 2 
(13343.1) 
1668.9(+8) 1483.6(+9) 
1335.3(+10) 1214.0(+11) 
1112.9(+12) 1027.4(+13) 
954.1(+14) 
13334.5 ± 0.2 
(13334.60) 
Cystatin C-Moxg 
(P01034) 
38.1-38.7 
13360 ± 2 
(13359.1) 
1670.8(+8) 1485.2(+9) 
1336.8(+10) 1215.4(+11) 
1114.2(+12) 1028.6(+13) 
955.2(+14) 
13354.4 ± 0.2 
(13354.59) 
α-defensin 1  
(P59665) 
24.9-25.4 
3442.1 ± 0.4  
(3442.1) 
1722.0(+2) 1148.4(+3) 861.5(+4) 
3439.53 ± 0.06 
(3439.519) 
α-defensin 2  
(P59665 and P59666) 
24.9-25.4 
3371.0 ± 0.4  
(3371.0) 
1686.5(+2) 1124.7(+3) 843.8(+4) 
3368.49 ± 0.06 
(3368.482) 
α-defensin 3  
(P59666) 
24.9-25.4 
3486.1 ± 0.4  
(3486.1) 
1744.0(+2) 1163.0(+3) 
872.5(+4) 
3483.52 ± 0.06 
(3483.509) 
α-defensin 4  
(P12838) 
27.7-28.0 
3709.3 ± 0.4  
(3709.5) 
1855.7(+2) 1237.5(+3) 
928.4(+4) 
3706.78 ± 0.06 
(3706.767) 
Thymosin β4  
(P62328) 
20.7-21.0 
4962.5 ± 0.4 
(4963.5) 
1655.5(+3) 1241.9(+4) 
993.8(+5) 
4960.51 ± 0.08 
(4960.494) 
Thymosin β4-Mox 
(P62328) 
19.0-19.2 
4979.4 ± 0.4 
(4979.5) 
1660.8(+3) 1245.9(+4) 
996.9(+5) 
4976.40 ± 0.08 
(4976.488) 
Thymosin β10 
(P63313) 
22.0-22.4 
4936.3 ± 0.4 
(4936.5) 
1646.5(+3) 1235.1(+4) 
988.3(+5) 
4933.44 ± 0.08 
(4933.530) 
S100A7 (D27) 
(P31151h) 
37.4-38.0 
11367 ± 2 
(11367.8) 
1422.0(+8) 1264.1(+9) 
1137.8(+10) 1034.4(+11) 
11360.3 ± 0.2 
(11360.53) 
S100A12  
(P80511) 
39.5-40.2 
10444 ± 2 
(10443.9) 
1306.5(+8) 1161.4(+9) 
1045.4(+10) 950.4(+11) 
10437.7 ± 0.2 
(10437.49) 
S100A8  
(P05109) 
39.1-39.7 
10833 ± 2 
(10834.5) 
1355.3(+8) 1204.8(+9) 
1084.5(+10) 985.9(+11) 
10827.8 ± 0.2 
(10827.66) 
S100A9(S)  
(P06702) 
41.3-42.0 
12690 ± 2 
(12689.2) 
1410.9(+9) 1269.9(+10) 
1154.6(+11) 1058.4(+12) 
977.1(+13) 
12681.4 ± 0.2 
(12681.29) 
S100A9(S) 
monophosphorylated 
(P06702) 
41.3-42.0 
12770 ± 2 
(12769.2) 
1419.8(+9) 1277.9(+10) 
1161.8(+11) 1065.1(+12) 
983.3(+13) 
12761.1 ± 0.2 
(12761.26) 
S100A9(S)-Mox 
(P06702) 
41.3-42.0 
12706 ± 2 
(12705.2) 
1412.7(+9) 1271.5(+10) 
1156.0(+11) 1059.8(+12) 
978.3(+13) 
12697.4 ± 0.2 
(12697.29) 
S100A9(S)-Mox 
monophosphorylated 
(P06702) 
41.3-42.0 
12786 ± 2 
(12785.2) 
1421.9(+9) 1279.5(+10) 
1163.3(+11) 1066.4(+12) 
984.5(+13) 
12777.2 ± 0.2 
(12777.25) 
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S100A9(L)-SSG 
(P06702) 
41.1-41.8 
13459 ± 2 
(13458.1) 
1346.8(+10) 1224.5(+11) 
1122.5(+12) 1036.3(+13) 
962.3(+14) 
13449.7 ± 0.2 
(13449.55) 
S100A9(L)-SSG 
monophosphorylated 
(P06702) 
41.1-41.8 
13539 ± 2 
(13538.1) 
1354.8(+10) 1231.8(+11) 
1129.2(+12) 1042.4(+13)  
968.0(+14) 
13529.3 ± 0.2 
(13529.52) 
S100A9(L)-SSG/Mox 41.0-41.6 
13475 ± 2 
(13474.1) 
1348.4(+10) 1225.9(+11)  
1123.8(+12) 1037.5(+13) 
963.4(+14) 
13465.6 ± 0.2 
(13465.55) 
S100A9(L)-SSG/Mox 
monophosphorylated 
41.0-41.6 
13555 ± 2 
(13554.1) 
1356.4(+10) 1233.2(+11) 
1130.5(+12) 1043.6(+13)  
969.1(+14) 
13545.7 ± 0.2 
(13545.52) 
S100A9(L)-SSC 
(P06702) 
41.1-41.8 
13273 ± 2 
(13271.9) 
1328.2(+10) 1207.6(+11) 
1107.0(+12) 1021.9(+13) 
949.0(+14) 
13263.5 ± 0.2 
(13263.49) 
S100A9(L)- SSC 
monophosphorylated 
(P06702) 
41.1-41.8 
13353 ± 2 
(13351.9) 
1336.2(+10) 1214.8(+11) 
1113.7(+12) 1028.1(+13)  
954.7(+14) 
13343.3 ± 0.2 
(13343.46) 
aPhosphorylation; bPRP-1 type includes the three entire isoforms PRP-1, PRP-2, and Pif-s, with a 
mass difference of 1 Da; cPRP-3 type includes the truncated isoforms PRP-3, PRP-4 and Pif-f; 
ddisulfide bridge; nd: not determined; eglutathionylated cysteine residue; fcysteinylated 
cysteine residue; gmethionine sulfoxide; hSwiss-Prot code refers to the variant E27. 
Statistical analysis 
GraphPad Prism was used for statistical analysis (the version 4.0 for Wilson’s 
disease and SAPHO syndrome studies and the version 5.0 for Hereditary 
angioedema study). A normality test was applied to calculate ranges, medians, 
means, and standard deviations of the XIC peak areas of the peptides and 
proteins. A t-test was used to compare proteins/peptides XIC peak areas 
between two different groups. Specifically, a non-parametric t-test was chosen 
if the distribution of the XIC peak areas was not Gaussian for at least one of the 
two groups (Mann-Whitney t-test), while a parametric test was employed if the 
distribution was Gaussian for both groups (Unpaired t-test). Welch’s correction 
was applied if the variance resulted significantly different between the groups. 
Statistical analysis was considered to be significant when the p value was <0.05 
(two tailed). One-way ANOVA was used to compare three or more groups. In 
particular, non-parametric tests were applied if the distribution of the data was 
not Gaussian for at least one of the groups (Kruskal-Wallis test with Dunn’s 
multiple comparison test) while a parametric test was employed if the 
distribution was Gaussian for all the groups (one-way analysis of variance with 
Tukey’s multiple comparison test).  
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Bottom-up proteomics experiments 
Quantification of proteins by nano-HPLC-ESI-MS experiments 
Abundance of the proteins identified in the acidic insoluble fractions by Mascot 
software, and considered confident according to the above reported criteria, 
was estimated for each group on the basis of the Exponentially Modified 
Protein Abundance Index (emPAI). The log2 ratio between the median emPAI 
values for each protein in any two groups was calculated to evidence 
differences. Proteins with logarithm values lower than -0.7 were considered 
significantly increased in the group in the denominator position with respect to 
the group in the numerator, while proteins with logarithm values higher than 
+0.7 were considered significantly increased in the group in the numerator 
position with respect to the group in the denominator. 
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Results 
 Wilson’s disease 
The following proteins and peptides were searched and quantified by top-down 
low-resolution HPLC-ESI-IT-MS experiments in the acidic soluble fraction of 
saliva from Wilson’s disease patients and healthy controls: histatins, salivary 
cystatins, statherin, P-B peptide, aPRPs, α-defensins 1–4, cystatins A, B, C, β-
thymosins 4 and 10, S100A7 (D27), S100A8, S100A9 (short (S) and long (L) 
isoforms), S100A12, as well as numerous their derivatives (Table 3). In addition, 
several masses not previously characterized were detected, and attributed to 
two naturally occurring fragments of pIgR and to proteoforms of S100A8 and 
S100A9 with a different degree of oxidation (Table 4). Characterization was 
performed by an integrated high-resolution HPLC-ESI-MS/MS top-down and 
bottom-up approach.  
High-resolution top-down structural characterization of pIgR, and three 
S100A8 oxidized proteoforms 
The structural characterization was performed on the acidic soluble fraction 
from patient whole saliva by high-resolution HPLC-ESI-MS/MS analysis. 
Two peptides, eluting in the region 23.4-27.0 min of the low-resolution HPLC-
ESI-MS profile of saliva, were identified as the fragment 610-648 and 623-648 of 
pIgR and respectively named AVAD and ASVD (Table 4). The identification 
was based on the high-resolution MS/MS performed on the AVAD triply-
charged ion 1278.62 ± 0.02 m/z and on the ASVD doubly-charged ion 1246.12 ± 
0.02 m/z, as shown in Fig.4 and Fig.5. 
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Table 4. Swiss-prot code, elution time, experimental (Exp.) and theoretical 
(Th.) average and monoisotopic mass values (Mav., Mmonois.), and multiply 
charged ions used for XIC quantification of ASVD and AVAD peptides, and 
S100A8 and S100A9 oxidized proteoforms.  
Protein 
(Swiss-Prot code) 
El. time 
(min) 
Exp. Mav. 
(Th. Mav.) 
Da 
Multiply-charged ions 
(m/z(charge)) 
Exp. Mmonois. 
(Th. Mmonois.) 
Da 
AVAD (pIgR fr.       
610-648 - P01833) 
25.4-25.8 
3834.4 ± 0.3 
(3834.1) 
1918.0(+2) 1279.0(+3) 
959.5(+4) 
3831.85 ± 0.06 
(3831.854) 
ASVD (pIgR fr.       
623-648 - P01833) 
25.8-26.1 
2490.5 ± 0.3 
(2490.7) 
1246.3 (+2) 831.2(+3) 
2490.23 ± 0.04 
(2489.232) 
S100A8-SO2H 39.7-40.0 
10866 ± 2 
(10866.5) 
1359.3(+8) 1208.4(+9) 
1087.7(+10) 988.9(+11) 
10859.6 ± 0.2 
(10859.65) 
S100A8-SO3H/W54ox 40.2-40.6 
10898 ± 2 
(10898.6) 
1363.3(+8) 1212.0(+9) 
1090.9(+10) 991.8(+11) 
10891.7 ± 0.2 
(10891.66) 
Hyper-oxidized 
S100A8 
39.0-39.6 
10915 ± 2 
(10914.6) 
1365.3(+8) 1213.7(+9) 
1092.5(+10) 993.2(+11) 
10907.6 ± 0.2 
(10907.63) 
S100A8-SSGa 38.1-38.4 
11140 ± 2 
(11139.8) 
1393.5(+8) 1238.8(+9) 
1115.0(+10) 1013.7(+11) 
11133.8 ± 0.2 
(11133.72) 
S100A8-SNOb 40.6-40.9 
10863 ± 2 
(10863.5) 
1358.9(+8) 1208.1(+9) 
1087.3(+10) 988.6(+11) 
10856.6 ± 0.2 
(10856.65) 
S100A8/A9-SScdimer 41.6-41.9 
23986 ± 3 
(23985) 
1600.0(+15) 1500.1(+16) 
1411.9(+17) 1333.5(+18) 
1263.4(+19) 1200.3(+20) 
1143.2(+21) 1091.2(+22) 
1043.8(+23) 1000.4(+24) 
960.4(+25) 923.5(+26) 
nd 
S100A9/A9-SSdimer 41.7-42.5 
26306 ± 3 
(26304) 
1754.6(+15) 1645.0(+16) 
1548.3(+17) 1462.3(+18) 
1385.4(+19) 1316.2(+20) 
1253.5(+21) 1196.6(+22) 
1144.6(+23) 1097.0(+24) 
1053.1(+25) 1012.7(+26) 
nd 
aglutathionylated cysteine residue; bnitrosylated cysteine residue; cdisulfide bridge; nd: not 
determined. 
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Fig.4 AVAD peptide. Annotated [M+H]+ deconvoluted spectrum of high-resolution MS/MS from 1278.62 m/z ([M+3H]3+).  
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Fig.5 ASVD peptide. Annotated [M+H]+ deconvoluted spectrum of high-resolution MS/MS from 1246.12 m/z ([M+2H]2+).
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S100A8 oxidation involved methionine 1 and 78 (M1, M78), tryptophan 54 
(W54), and cysteine 42 (C42). Three proteoforms of S100A8 showed C42 
oxidized to sulfonic acid (S100A8-SO3H). The first presented a further oxidation 
at W54 (S100A8-SO3H/W54ox), as shown by the high-resolution MS/MS 
annotated spectra reported in Fig.6A-C, while Fig.7A-C shows the MS/MS 
spectra of the other two forms, which were isobaric derivatives of S100A8-SO3H 
(Hyper-oxidized S100A8): one form was also oxidized at W54 and M78 
(S100A8-SO3H/W54ox/M78ox), the other was dioxidized at W54 (S100A8-
SO3H/W54diox). All these S100A8 proteoforms are reported in Table 4. The 
neutral loss of H2SO3 (81.97 Da) (Shetty, 2007) observed only for S100A8-
SO3H/W54ox and for S100A8-SO3H/W54ox/M78ox was in agreement with the 
presence of the sulfonic acid residue, and MS/MS data of the ion 910.56 m/z 
([M+12H]+12) confirmed the structures of the two co-eluting and isobaric hyper-
oxidized S100A8 proteoforms. Top-down high-resolution MS/MS annotated 
spectra of intact S100A8-SO3H/W54ox and hyper-oxidized S100A8 forms are 
respectively shown in Fig.6A-C and Fig.7A-C. 
High-resolution bottom-up structural characterization of S100A8, S100A9 
oxidized proteoforms  
Trypsinized enriched fractions of S100A8, S100A9 and their oxidized 
proteoforms obtained by pools of patient saliva samples were analyzed by 
high-resolution HPLC-ESI-MS/MS. The bottom-up approach allowed 
confirming S100A8-SO3H and characterizing other oxidized derivatives of 
S100A8. MS/MS sequencing of the tryptic peptides with monoisotopic [M+H]+ 
1412.68 ± 0.02 and 1540.77 ± 0.03 m/z corresponding to S100A8-SO3H fragments 
37-47, 37-48, and 36-47 (the latter two isobaric) confirmed the sulfonic acid 
modification of C42 (Table 5, Fig. 8A-C).  
One proteoform of S100A8 with C42 oxidized to sulfinic acid (S100A8-SO2H, 
10859.6 ± 0.2 Mmonois., Table 4) was confirmed by MS/MS of the tryptic 
peptide 37-47 (Table 5, Fig.9) which showed the characteristic neutral loss of 
H2SO2 (65.98 Da) (Wang, 2004). The Mmonois. 10859.6 ± 0.2 could be also in 
agreement with dioxidized derivatives of S100A8, i.e. at W54 and M1, or M78 
and M1, or W54 and M78. This possibility could not be excluded nor confirmed 
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by high-resolution MS/MS due to the separation of the modification sites in the 
tryptic peptides (Table 5). Oxidation of M1 in S100A8 was evidenced by 
MS/MS data of the tryptic peptide 1-23 (Table 5, Fig.10). Furthermore, masses 
attributable to tryptic peptides oxidized at M78 and W54, but not confirmed by 
MS/MS due to the low intensity, were also detected. The tentative attributions 
and monoisotopic [M+H]+ m/z values were: fragment 78-84 of S100A8-M78ox, 
with m/z 729.32 ± 0.01 (theor. 729.38) eluting at 20.7 min; fragment 50-56 of 
S100A8-W54ox, with m/z 838.35 ± 0.01 (theor. 838.41, 20.7 min); fragment 48-56 
of S100A8-W54ox, with m/z 1110.47 ± 0.02 (theor. 1110.59, 22.0 min).  
Glutathionylation of C42 in S100A8 (S100A8-SSG, Table 4) was demonstrated 
by MS/MS data of the 37-47 glutathionylated peptide (monoisotopic 
monocharged ion with m/z 1669.76 ± 0.03, Table 5). Fig. 11A shows the high-
resolution MS/MS of the triply-charged ion with m/z 557.26 with the 
characteristic neutral loss of pyroglutamate (129.04 Da), that confirmed the 
presence of the glutathionyl moiety.  
The monoisotopic mono-charged ions with m/z 1649.78 ± 0.03 and 1393.73 ± 0.02 
were tentatively attributed to the following fragments of C42-nitrosylated 
S100A8 (S100A8-SNO, Table 4): 37-49 (or 36-48) fragment (theor. 1649.87 m/z) 
and 37-47 fragment (theor. 1393.68 m/z).  
Cysteine 42 of S100A8 originated also a disulfide bridge with cysteine 3 of 
S100A9(L) (S100A8/A9-SSdimer, Table 4). The presence in saliva of Wilson’s 
disease patients of this covalent hetero-dimer was confirmed by high-resolution 
MS/MS of the monoisotopic doubly-charged ion with m/z 877.93 ± 0.01, 
attributed to the tryptic peptide in which peptide fragment 2-4 of S100A9(L) 
was linked to fragment 37-47 of S100A8 (Fig. 11B, Table 5). The monoisotopic 
mono-charged ion with m/z 2628.26 ± 0.04 was attributed to peptide fragment 2-
10 of S100A9(L) linked to peptide fragment 36-47 of S100A8, but not confirmed 
by MS/MS data due to its low abundance. The two peptides, with the following 
experimental monoisotopic [M+H]+ m/z values: 784.49 ± 0.01 and 1528.72 ± 0.03 
were tentatively attributed to Nα-Ac-TCK dimer (theor. 784.36 m/z), and Nα-
Ac-TCK bound to Nα-Ac-TCKMSQLER (theor. 1528.72 m/z), respectively, 
generated by S100A9(L)-SSdimer (Table 4).  
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Both the short and the long glutathionylated S100A9 proteoforms were detected 
as mono-oxidized derivatives on one of the following methionine residues: M59 
(or M63), M77 (or M81), M79 (or M83), and M90 (or M94) (Table 4), as 
confirmed by high-resolution MS/MS of the mono-oxidized tryptic peptides 
reported in Table 5 and shown in Fig.12 and Fig.13. 
Table 5.  Experimental and theoretical monoisotopic [M+H]+ mass values, 
elution time, sequence, PTMs, and m/z values selected for high-resolution 
HPLC-ESI-MS/MS analysis of the tryptic peptides obtained by digestion of 
enriched fractions of S100A8 and S100A9 oxidized proteoforms. 
Tryptic Peptides 
Exp. and (Th.) monois. 
[M+H]+ 
(Elution time, min) 
Sequence and position PTMs 
Ion selected 
for MS/MS 
analysis 
m/z  
(charge) 
S100A8 
2737.49 ± 0.04 (2737.48)         
(39.1) 
mLTELEKALNSIIDVYHKYSLIK 
1-23 
M-sulfoxide 
685.13  
(+4) 
1540.77 ± 0.03 (1540.77)         
(20.2) 
KLLETEcPQYIR 
36-47 
C-sulfonic acid 
770.89 
(+2) 
1540.77 ± 0.03 (1540.77)        
(18.5) 
LLETEcPQYIRK 
37-48 
C-sulfonic acid 
770.89  
(+2) 
1669.76 ± 0.03 (1669.76)         
(19.7) 
LLETEcPQYIR 
37-47 
C-
glutathionylation 
557.25  
(+3) 
1412.68 ± 0.02 (1412.67)         
(20.2) 
LLETEcPQYIR 
37-47 
C-sulfonic acid 
706.84  
(+2) 
1396.68 ± 0.02 (1396.68)         
(19.9) 
LLETEcPQYIR 
37-47 
C-sulfinic acid 
698.84  
(+2) 
S100A8/A9-SSdimer 
1754.86 ± 0.03 (1755.87)         
(19.5) 
LLETEcPQYIR 37-47 (S100A8) 
¦ 
Nα-Acet-TcK 2-4 (S100A9) 
C-disulfide 
dimerization 
877.93 
(+2) 
S100A9 
1630.80 ± 0.03 (1630.80)          
(37.3) 
QLSFEEFImLMAR 
73-85 
M-sulfoxide 
815.90  
(+2) 
1630.80 ± 0.03 (1630.80)          
(32.7) 
QLSFEEFIMLmAR 
73-85 
M-sulfoxide 
 
815.90  
(+2) 
1758.82 ± 0.03 (1758.82)            
(18.3) 
VIEHImEDLDTNADK 
57-72 
M-sulfoxide 
879.91  
(+2) 
3354.61 ± 0.06 (3354.61)            
(35.8) 
VIEHIMEDLDTNADKQLSFEEFI
mLMAR 
57-85 
M-sulfoxide 
839.41 
(+4) 
2191.96 ± 0.04 (2191.96)            
(12.1) 
mHEGDEGPGHHHKPGLGEGTP 
94-114 
M-sulfoxide 
731.32  
(+3) 
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Fig.6A S100A8-SO3H/W54ox. Annotated [M+H]+ and enlargement in the mass range 6949-8017 m/z of the deconvoluted spectrum of 
high-resolution MS/MS from 909.15 m/z ([M+12H]12+). 
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Fig.6B  S100A8-SO3H/W54ox. Enlargement in the mass range 2200-3842 m/z. of the annotated [M+H]+ deconvoluted spectrum of high-
resolution MS/MS from 839.29 m/z ([M+13H]13+).  
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Fig.6C  S100A8-SO3H/W54ox. Enlargement in the mass range 6938-7993 m/z. of the annotated [M+H]
+ deconvoluted spectrum of high-
resolution MS/MS from 839.29 m/z ([M+13H]13+).   
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Fig.7A Hyperoxidized S100A8; S100A8-SO3H/W54ox/M78ox. Annotated [M+H]
+ deconvoluted spectrum of high-resolution MS/MS 
from 910.48 m/z ([M+12H]12+). 
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Fig.7B Hyperoxidized S100A8; S100A8-SO3H/W54ox/M78ox. and S100A8-SO3H/W54diox. Annotated [M+H]
+ deconvoluted spectrum 
of high-resolution MS/MS from 910.56 m/z ([M+12H]12+). The first y and b ion’s series (blue and red) are in agreement with C42- SO3H 
(+47.985 Da), W54-oxidized (+15.995 Da) and M78-oxidized (+15.995 Da) modifications. The second y and b ion’s series (green and 
pink) are in agreement with C42- SO3H (+47.985 Da) and W54-dioxidized (+31.999 Da) modifications. 
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Fig.7C Hyperoxidized S100A8; S100A8-SO3H/W54ox/M78ox. and S100A8-SO3H/W54diox. Enlargement in the range 7068-7860 m/z of 
the annotated [M+H]+ deconvoluted spectrum of high-resolution MS/MS from 910.56 m/z ([M+12H]12+).  
~ 53 ~ 
 
 
Fig.8 Sulfonic acid modification of C42 of S100A8 (C42-SO3H): fragment 37-47, panel A; 37-48, panel B; 36-47, panel C. 
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Fig.9 Sulfinic acid modification of C42 of S100A8 (C42-SO2H): fragment 37-47. 
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Fig.10 Oxidation on M1 of S100A8 (M1ox), fragment 1-23. 
  
Fig.11 Glutathionylation of C42 in S100A8 (S100A8-SSG), panel A; disulfide bridge between cysteine 42 of S100A8 and cysteine 3 of 
S100A9(L) (S100A8/A9-SSdimer), panel B.
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Fig.12 Oxidation on M81 of S100A9 (M81ox): fragment 73-85, panel A; fragment 57-85, panel B.  
Oxidation on M83 of S100A9 (M83ox): fragment  73-85, panel C. 
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Fig.13 Oxidation on M63 of S100A9 (M63ox): fragment 57-72, panel A. Oxidation on M94 of S100A9 (M94ox): fragment 94-114, panel B.  
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Protein/peptide quantification and statistical analysis 
T-test was used to compare the XIC peak area of each protein/peptide 
measured by low-resolution HPLC-ESI-IT-MS in Wilson’s disease patients and 
healthy controls (Table 6).  
Table 6. XIC peak area (mean ± standard deviation (SD) and median x107) and 
frequency of pIgR fragments, α-defensins 2-4, and several proteoforms of 
S100A8, and S100A9 in Wilson’s disease patients and healthy controls. T-test p 
value obtained by comparing the two groups are also reported.  
Peptide/protein 
WD group 
Mean ± SD 
Median 
Frequency 
HC group 
Mean ± SD 
Median 
Frequency p value 
ASVD 
1.1 ± 0.6 
1.1 
30/32 
0.7 ± 0.7 
0.5 
21/32 0.02 ↑ 
AVAD 
2.4 ± 1.2 
2.2 
31/32 
1.3 ± 1.1 
1.4 
21/32 0.003 ↑ 
α-Defensin 2 
9.3 ± 11.0 
4.3 
27/32 
4.7 ± 5.1 
2.7 
25/32 0.04 ↑ 
α-Defensin 4 
2.5 ± 2.8 
1.2 
24/32 
0.8 ± 1.7 
0.01 
11/32 0.004  ↑ 
S100A9(S) 
(1P + non-P) 
27.4 ± 30.4 
14.8 
27/32 
9.6 ± 12.1 
4.5 
19/32 0.004  ↑ 
S100A9(S)-Moxa 
(1P + non-P) 
5.0 ± 8.0 
1.4 
16/32 
2.4 ± 5.0 
0.01 
9/32 ns 
S100A9(L)-SSGb 
(non-P) 
15.9 ± 19.3 
7.5 
24/32 
5.0 ± 7.6 
0.01 
15/32 0.007 ↑ 
S100A9(L)-SSCc 
(1P + non-P) 
2.3 ± 5.1 
0.01 
8/32 
0.3 ± 1.5 
0.01 
3/32 ns 
S100A9/A9-SSddimer 
1.7 ± 4.6 
0.01 
5/32 0  na 
S100A8/A9-SSdimer 
5.1 ± 13.8 
0.01 
5/32 0  na 
S100A9(L)ox tot 
28.6 ± 31.9 
18.8 
29/32 
8.9 ± 13.4 
1.9 
15/32 0.006 ↑ 
S100A8 
3.1 ± 4.7 
0.01 
15/32 
0.5 ± 1.6 
0.01 
4/32 0.01  ↑ 
Hyperoxidized S100A8 
3.0 ± 3.7 
1.6 
20/32 
0.7 ± 1.6 
0.01 
7/32 0.002  ↑ 
S100A8-SO3H/W54ox 
1.1 ± 3.2 
0.01 
11/32 
0.3 ± 0.8 
0.01 
5/32 ns 
S100A8-SSG 
0.5 ± 1.5 
0.01 
5/32 0  na 
S100A8-SNOe 
2.7 ± 9.0 
0.01 
5/32 0  na 
S100A8-SO2H 
0.3 ± 0.9 
0.01 
3/32 0  na 
S100A8ox tot 
10.4 ± 14.8 
4.3 
23/32 
0.9 ± 1.8 
0.01 
11/32 0.0003 ↑ 
amethionine sulfoxide; bglutathionylated cysteine residue; ccysteinylated cysteine residue; 
ddisulfide bridge; ns: not significant; na: not applicable; enitrosylated cysteine residue; ↑: 
increased levels in WD group. 
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No statistical differences were found in the levels of proteins and peptides 
secreted by salivary glands, such as histatins, statherin, P-B peptide, cystatins S 
and C, and aPRPs, as well as in the level of cystatin A and B. Conversely, saliva 
of Wilson’s disease patients with respect to healthy subjects showed significant 
higher levels of AVAD and ASVD pIgR peptides, and α-defensins 2 and 4 
(Table 6, Fig.14A-B).  
      
Fig.14 Distribution of the XIC peak area values of ASVD and AVAD peptides 
(A) and α-defensins 2 and 4 (B) measured in saliva from Wilson’s disease 
patients and healthy controls. Asterisk indicates statistically significant 
differences: *(p < 0.05), **(p ≤ 0.01). 
Moreover, S100A9(S), S100A9(L)-SSG, and their phosphorylated derivatives, 
S100A8 and hyper-oxidized S100A8 exhibited higher levels in saliva of patients 
with respect to controls (Table 6, Fig.15A-B). Statistical analysis was performed 
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considering the totality of non-phosphorylated and phosphorylated forms of 
short and long S100A9 and the results are reported in Table 6.  
 
Fig.15 Distribution of the XIC peak area values of S100A9(S) and S100A9(L)-SSG 
(A) and S100A8 and hyper-oxidized S100A8 (S100A8-SO3H/W54ox/W54-
ox/M78-ox or -SO3H/W54diox (B) measured in saliva from Wilson’s disease 
patients and healthy controls. Asterisk indicates statistically significant 
differences: *(p < 0.05), **(p ≤ 0.01). 
Wilson’s disease patients showed higher levels and frequencies of S100A8-
SO3H/W54ox, S100A9(L)-SSC, S100A9(L)-SSC phosphorylated, S100A9(S)-Mox 
and S100A9(S)-Mox phosphorylated with respect to controls, even though 
without a statistical significance (Table 6). In patients with high concentration of 
S100A8 and S100A9, also the following modifications were detected, even if 
sporadically: S100A8-SSG and S100A8-SNO in 5 patients; S100A8-SO2H in 3 
patients, S100A8/A9-SSdimer and S100A9(L)-SSdimer in 8 patients (Table 6). In 
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8 Wilson’s disease patients S100A8 was detected only in the oxidized forms. 
Statistical analysis highlighted significant higher levels in patients with respect 
to healthy subjects of the totality of the oxidized proteoforms of S100A8 
(S100A8ox tot), and the totality of the oxidized proteoforms of S100A9(L) 
(S100A9(L)ox tot) (Table 6, Fig.16).  
       
Fig.16 Distribution of the XIC peak area values of total S100A8ox and 
S100A9(L)ox measured in saliva from Wilson’s disease patients and healthy 
controls. Asterisk indicates statistically significant differences:                           
**(p ≤0.01), ***(p ≤ 0.001). 
A calculation of the relative abundance of the different proteoforms revealed 
that S100A8 was mainly represented by its oxidized derivatives in saliva of both 
patients and controls: 75 ± 30% in Wilson’s disease patients, 77 ± 42% in healthy 
subjects. Among the oxidized proteoforms the most abundant was the hyper-
oxidized S100A8 (WD 42 ± 40%, controls 59 ± 46%), followed by S100A8-
SO3H/W54ox (WD 12 ± 23%, controls 18 ± 32%), S100A8/A9-SSdimer (WD 11 ± 
27%), S100A8-SNO (WD 8 ± 22%), S100A8-SSG (WD 1 ± 3%), and S100A8-SO2H 
(WD 1 ± 4%).  
Both in patients and controls, S100A9(L) was detected only in the form oxidized 
at the cysteine residue: glutathionylated (WD 85 ± 16%, HC 98 ± 5%), 
cysteinylated (WD 7 ± 10%, 375 HC 2 ± 5%), and dimeric (WD 8 ± 13%). 
Conversely, S100A9(S) was prevalently detected in the non-oxidized forms in 
Wilson’s disease patients (86 ± 24%), and healthy subjects (80 ± 35%). 
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 SAPHO syndrome 
The following proteins and peptides were searched and quantified by top-down 
low-resolution HPLC-ESI-IT-MS experiments in the acidic soluble fraction of 
saliva from SAPHO patients and healthy controls: histatins, salivary cystatins, 
statherin, P-B peptide, aPRPs, α-defensins 1–4, cystatins A, B, C, β-thymosins 4 
and 10, S100A7 (D27), S100A8, S100A9 (short (S) and long (L) isoforms), 
S100A12, as well as numerous their derivatives (Table 3).  
Protein/peptide quantification and statistical analysis 
T-test was used to compare the XIC peak area of each protein/peptide 
measured by low-resolution HPLC-ESI-IT-MS in SAPHO patients and healthy 
controls. The XIC peak areas mean ± SD (x107), the frequency and the p value 
obtained on proteins showing differences between the two groups are reported 
in Table 7. 
Table 7. 
Proteins 
SAPHO patients 
mean ± SD    Frequency 
Healthy controls 
mean ± SD    Frequency 
p value 
Salivary cystatins      
Cystatin S1             60.4 ± 58.7 10/10 122.2 ± 118.6 26/28 0.04 
Cystatin SN              115.2 ± 132.4 10/10 199.1 ± 189.1 25/28 ns 
Histatins      
Histatin 1                          21.5 ± 14.1 9/10 40.8 ± 25.8 28/28 0.007 
Histatin 3                          11.1 ± 19.0 6/10 17.5 ± 16.9 18/28 ns 
Histatin 6 (1/25)                10.5 ± 16.7 8/10 15.6 ± 11.5 27/28 ns 
Histatin 5 (1/24)                26.7 ± 33.0 10/10 48.6 ± 30.8 28/28 ns 
S100A12                         3.4 ± 3.6 6/10 1.2 ± 2.6 6/28 ns 
aPRPs      
PRP-1 diphos 629.8 ± 361.5 10/10 981.0 ± 511.2 28/28 ns 
PRP-3 diphos 178.2 ± 77.2 10/10 364.9 ± 176.1 28/28 <0.0001 
P-C peptide 144.1 ± 80.2 10/10 246.1 ± 95.1 28/28 0.005 
P-B peptide 195.0 ± 115.9 10/10 304.2 ± 169.4 28/28 ns 
ns: not significant 
The results of the statistical analysis performed by excluding from the SAPHO 
group the patient #8, who unlike the others never had skin manifestations 
(Table 1), are reported in  Table 8. 
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Table 8. 
Proteins 
SAPHO patients 
mean ± SD    Frequency 
Healthy controls 
mean ± SD    Frequency 
p value 
Salivary cystatins 
Cystatin S1                 52.2 ± 55.6 9/9 122.2 ± 118.6 26/28 0.02 
Cystatin SN                 83.1 ± 90.3 9/9 199.1 ± 189.1 25/28 0.02 
Histatins 
Histatin 1                   21.1 ± 14.8 8/9 40.8 ± 25.8 28/28 0.04 
Histatin 3                          5.4 ± 6.6 5/9 17.5 ± 16.9 18/28 0.004 
Histatin 6 (1/25)                5.4 ± 5.1 7/9 15.6 ± 11.5 27/28 0.0009 
Histatin 5 (1/24)                17.0 ± 13.0 9/9 48.6 ± 30.8 28/28 0.0001 
S100A12                         3.8 ± 3.6 6/9 1.2 ± 2.6 6/28 0.04 
aPRPs 
PRP-1 diphos 535.3 ± 215.9 9/9 981.0 ± 511.2 28/28 0.0008 
PRP-3 diphos 161.2 ± 58.8 9/9 364.9 ± 176.1 28/28 <0.0001 
P-C peptide 121.4 ± 37.5 9/9 246.1 ± 95.1 28/28 <0.0001 
P-B peptide                                      167.8 ± 82.3 9/9 304.2 ± 169.4 28/28 0.003 
Among salivary cystatins, only cystatin S1 showed a significant lower level in 
the SAPHO subjects with respect to healthy controls (p = 0.04), but  exclusion of 
the patient #8 evidenced a significant lower concentration of also cystatin SN (p 
= 0.02) (Table 8, Fig.17). 
 
Fig.17 Distribution of the XIC peak area values of cystatins S1 (panel A) and SN 
(B) measured in saliva from SAPHO patients (patient #8 excluded) and healthy 
controls. Asterisk indicates statistically significant differences: *p < 0.05. 
Histatin 1 concentration (p = 0.007) was found deeply lower in saliva of SAPHO 
patients as compared with controls (Fig.18A), while the level of histatins 3, 5, 
and 6 was similar in the two groups (Table 7). Distribution of XIC peak areas 
showed that concentration of the last three peptides was extremely higher in 
patient #8 with respect to both SAPHO and control subjects. By excluding this 
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subject from the patient’s group, the level of histatins 3, 5 and 6 became 
significantly lower with respect to controls (Fig.18B-D), and the following p 
values were determined: 0.004, 0.0001, and 0.0009, for histatins 3, 5, and 6, 
respectively (Table 8). 
 
Fig.18 Distribution of XIC peak area values of histatin 1 (panel A), histatin 3 (B), 
histatin 5 (C) and histatin 6 (D)  measured in saliva from SAPHO patients 
(patient #8 excluded) and healthy controls. Asterisks indicate statistically 
significant differences: *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
Statistical analysis evidenced significant lower levels of diphosphorylated PRP3 
(p <0.0001) and the P-C peptide (p = 0.005) in saliva of SAPHO compared with 
the controls (Table 7). Also the levels of the P-C peptide and diphosphorylated 
PRP1 were higher in patient #8 than in the other patients. By excluding this 
subject, the level of diphosphorylated PRP1 resulted significantly different (p = 
0.0008, Table 8) in the two groups, and the p value for the P-C peptide became 
lower than 0.0001 (Fig.19A and Table 8). 
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The P-B peptide was less abundant in SAPHO patients than in controls, 
although the statistical analysis became significant only after the exclusion of 
the patient #8 (p = 0.003), as shown in Fig.19B. 
 
Fig.19 Distribution of XIC peak area values of the P-C peptide (panel A) and the 
P-B peptide (B) measured in saliva from SAPHO patiens (patient #8 excluded) 
and healthy controls. Asterisks indicate statistically significant differences:      
**p ≤ 0.01; *** p ≤ 0.001. 
S100A12 protein showed a higher frequency in the SAPHO group (6/10) with 
respect to the controls (6/28) (Table 7). The level of this protein became 
significantly higher in patients than in healthy controls by excluding the patient 
#8 (p = 0.04), as shown in Table 8. 
Correlations between low-resolution HPLC-ESI-IT-MS data and clinical and 
laboratory parameters 
The XIC peak areas of the salivary proteins/peptides quantified by low-
resolution HPLC-ESI-IT-MS experiments and showing significant quantitative 
variations between the two groups were correlated with SAPHO clinical 
laboratory parameters. A positive correlation was observed between CRP levels 
and the salivary concentration of all the histatins (p = 0.005, 0.004, 0.006, 0.006, 
for histatins 1, 3, 5, and 6, respectively; R = 0.8 for all of them, Fig. 20A-D). 
Moreover, CRP showed a negative correlation with S100A12 (p = 0.02; R = -0.7, 
Fig.20E). The cystatin SN abundance decreased in relation to the disease 
duration (p = 0.03; R = -0.7, Fig.20F). 
SAPHO HC
0
2.010 9
4.010 9
6.010 9
P-C peptide
SAPHO HC
0
2.510 9
5.010 9
7.510 9
P-B peptideX
IC
 p
e
a
k
 a
re
a
 (
a
rb
it
ra
ry
 u
n
it
)  
B A 
X
IC
 p
e
a
k
 a
re
a
 (
a
rb
it
ra
ry
 u
n
it
)  
*** 
 
** 
 
~ 66 ~ 
 
  
Fig.20 Correlation analysis between CRP and histatin 1 (panel A), histatin 3 (B), 
histatin 5 (C), histatin 6 (D), S100A12 (E), and between cystatin SN and the 
disease duration (F) in SAPHO patients. 
By excluding patient #8, the correlations between CRP and histatins were 
confirmed (p = 0.005, 0.008, 0.01, 0.02; R = 0.9, 0.8, 0.8, 0.8, for histatins 1, 3, 5, 
and 6, respectively), as well as the correlation between CRP and S100A12 (p = 
0.04; R = -0.7), while that between cystatin SN and the disease duration 
vanished. Histatin 3 correlated negatively with the erythrocyte sedimentation 
rate (p = 0.04, R = -0.7, Fig.21A), and positively with the total white cells count 
(p = 0.04, R = 0.7, Fig.21B). Moreover, the highest levels of histatin 3 (p = 0.01, R 
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= 0.8) and 5 (p = 0.01, R = 0.8) were measured in the SAPHO patients with 
higher blood neutrophil counts (Neu) (Fig.21C-D).  
   
Fig.21 Correlation analysis between histatin 3 and ESR (panel A), WBC (B) and 
neutrophil count (C), and between histatin 5 and neutrophil count (D) in 
SAPHO patients (patient #8 excluded). 
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 Hereditary angioedema 
The following proteins and peptides were searched and quantified by top-down 
low-resolution HPLC-ESI-IT-MS experiments in the acidic soluble fraction of 
saliva from angioedema patients and healthy controls: histatins, salivary 
cystatins, statherin, P-B peptide, aPRPs, α-defensins 1–4, cystatin B, β-
thymosins 4 and 10, S100A7 (D27), S100A8, S100A9 (short (S) and long (L) 
isoforms), S100A12, as well as several derivatives (see Table 3).  
Protein/peptide quantification and statistical analysis 
One-way ANOVA and Post-hoc Dunn’s multiple comparison test were used to 
compare the XIC peak area of each protein/peptide among the three 
angioedema groups and the control group and the results are shown in Table 9. 
Statistically significant differences were observed for S-glutathionylated 
cystatin B (cystatin B-SSG) (p = 0.0007) and S-cysteinylated cystatin B (cystatin 
B-SSC) (p = 0.003), and Post-hoc comparisons showed that both C1-INH-HAE 
and InH-AAE groups had significant higher levels of cystatin B-SSG with 
respect to the control group, while InH-AAE had higher levels of cystatin B-SSC 
compared to both healthy subjects and FXII-HAE patients (Fig.22A-B).  
Also lower levels of statherin Des-Thr42-Phe43 were observed in FXII-HAE 
patients with respect to C1-INH-HAE and control groups (p = 0.006).  
Moreover, histatin 1 and non-phosphorylated histatin 1 were significantly 
different among the groups (p = 0.04 and p = 0.01, respectively). In particular, in 
FXII-HAE patients higher levels of the two peptides were observed with respect 
to the healthy controls and increased levels of non-phosphorylated histatin 1 
were observed also as compared to C1-INH-HAE group.  
Finally, InH-AAE showed levels of S100A9(S)-Mox phosphorylated higher with 
respect to FXII-HAE group (p = 0.02). 
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Table 9.  XIC peak area means (± SD), and frequencies (Freq.) of proteins and peptides showing statistically different  
levels among C1-INH-HAE, FXII-HAE, Inh-AAE and control groups by one-way ANOVA. 
Protein name 
C1-INH-HAE FXII-HAE InH-AAE Controls        ANOVA 
Mean ± SD 
(x10^7) 
Freq. 
Mean ± SD 
(x10^7) 
Freq. 
Mean ± SD 
(x10^7) 
Freq. 
Mean ± SD 
(x10^7) 
Freq. p value 
Post-hoc Dunn’s multiple 
comparison test 
Cystatin B-SSGa 24.0 ± 16.0 13/13 14.6 ± 14.3 10/10 24.5 ± 13.5 12/12 10.4 ± 9.9 31/31 0.0007 
C1-INH-HAE > Controls ** 
InH-AAE > Controls ** 
Cystatin B-SSCb 5.3 ± 3.9 13/13 2.7 ± 2.1 10/10 7.3 ± 4.2 12/12 3.7 ± 4.4 31/31 0.003 
InH-AAE > FXII-HAE * 
InH-AAE > Controls ** 
Histatin 1 38.7 ± 39.5 11/13 52.1 ± 20.6 10/10 45.2 ± 30.2 12/12 29.5 ± 26.5 30/31 0.04 FXII-HAE > Controls * 
Non-
phosphorylated 
Histatin 1  
4.5 ± 7.3 8/13 9.3 ± 4.5 10/10 5.0 ± 4.4 9/12 4.2 ± 5.1 24/31 0.01 
FXII-HAE > C1-INH-HAE * 
FXII-HAE > Controls * 
Statherin  
Des-Thr42-Phe43 
6.5 ± 5.1 13/13 1.8 ± 1.5 10/10 5.1 ± 5.4 12/12 4.8 ± 3.7 31/31 0.006 
FXII-HAE < C1-INH-HAE ** 
FXII-HAE < Controls * 
S100A9(S)-Moxc 
phosphorylated 
0.9 ± 1.7 4/13 0.0 ± 0.0 0/10 2.3 ± 3.5 6/12 0.6 ± 1.9 5/31 0.02 InH-AAE > FXII-HAE * 
aglutathionylated cysteine residue; bcysteinylated cysteine residue; cmethionine sulfoxide.  
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Fig.22 Distribution of XIC peak area values of cystatin B-SSG (panel A) and cystatin B-
SSC (B) measured in saliva from C1-INH-HAE (circles), FXII-HAE (squares), InH-AAE 
(triangles) patients and healthy subjects (diamonds). Asterisks indicate statistically 
significant differences between pairs of groups (one way ANOVA with post-hoc 
Dunn’s multiple comparison test): *p < 0.05; **p ≤ 0.01. 
Characterization of the acidic insoluble salivary proteome and bioinformatic 
analyses 
Six available insoluble fractions obtained by treatment of whole saliva with TFA 
(3 from patients belonging to C1-INH-HAE group, 2 from patients belonging to 
FXII-HAE group and 1 from a Inh-AAE patient) were analyzed in duplicate by 
nano-HPLC-ESI-MS and MS/MS after tryptic digestion according with the 
endoProteoFASP protocol (bottom-up approach). A total of 191 distinct proteins 
were identified: 61 were common to all the three angioedema groups; 54 were 
shared between C1-INH-HAE and FXII-HAE groups; 31 between C1-INH-HAE 
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and Inh-AAE groups; and 30 between FXII-HAE and InH-AAE groups. 
Conversely, 7 proteins were specific of C1-INH-HAE group and 8 for FXII-HAE 
group (Fig.23). 
 
Fig.23 Venn diagram representing the distribution of identified proteins per 
group (C1-INH-HAE, in red; FXII-HAE, in blue; InH-AAE, in green) evidencing 
overlapped and unique proteins. 
The integrated analysis of all proteins identified in the three patient groups 
performed by Cytoscape_v3.2.1 with the additional plugin ClueGO+CluePedia, 
generated the protein-protein interaction network reported in Fig.24, consisting 
of 171 proteins, distributed in 18 clusters, connected by 714 protein-protein 
interactions. 
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Fig.24 
The most significant biological processes related to the identified proteins, 
shown in Fig. 25 with different colors according to their significance, were: 
detection of chemical stimulus involved in sensory perception of bitter taste; 
multicellular organismal and tissue homeostasis (retina and anatomical 
structure homeostasis and development); skin development (epidermal cell and 
keratinocyte differentiation); intermediate filament cytoskeleton organization; 
defense response to fungus; regulation of lipopolysaccharide-mediated 
signaling pathway; establishment of skin barrier; regulation of water loss via 
skin; protein nitrosylation; fibroblast proliferation, collagen fibril organization.  
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Fig.25 Protein interaction network generated with Cytoscape showing the most 
significant biological processes related to the identified proteins. The size of the 
rings indicates the number of proteins associate to each pathway, while 
different colors indicate the significance for each biological process represented  
(red: p < 0.05; red-purple: p < 0.005; brown: p < 0.0005). 
Fig.26 shows the identified proteins evidencing the distribution among the 
three angioedema groups. Each color identifies a specific angioedema group: 
red, C1-INH-HAE; blue, FXII-HAE; green, InH-AAE. 
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Fig.26 
Quantification of proteins characterized by nano-HPLC-ESI-MS experiments 
and statistical analysis  
Proteins which displayed significantly different abundance between pairs of the 
hereditary angioedema groups (log2 ratio between the median emPAI values of 
a specific protein in two groups lower than -0.7 or higher than +0.7) are shown 
in Fig.27. From the figure it is evident that 28 proteins showed a significant 
different level in C1-INH-HAE group with respect to InH-AAE groups, being 
10 more abundant in the C1-INH-HAE group, and 18 in the Inh-AAE group 
(Fig. 27A).  Conversely, 11 proteins were significantly more abundant and 22 
less abundant in FXII-HAE patients with respect to InH-AAE (Fig.27B). C1-
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INH-HAE group showed 18 proteins less abundant and 18 more abundant with 
respect to FXII-HAE group (Fig.27C).  
 
Fig.27 Base two logarithmic distribution of the emPAI values ratio calculated 
between pairs of angioedema groups. Comparison between C1-INH-HAE and 
Inh-AAE (panel A); FXII-HAE and Inh-AAE (panel B) and C1-INH-HAE and 
FXII-HAE (panel C). 
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In C1-INH-HAE group albumin (ALBU), amylase (AMY1) and carbonic 
anhydrase 6 (CAH6) were increased with respect to InH-AAE group (Fig.27A), 
while higher levels of cystatin A (CYTA) and salivary cystatin SN (CYTN) were 
observed with respect to FXII-HAE (Fig.27C). Moreover, lactotransferrin (TRFL) 
showed higher abundance with respect to both FXII-HAE (Fig.27C) and InH-
AAE (Fig.27A) groups. FXII-HAE group displayed increased levels of albumin 
and amylase than InH-AAE group (Fig.27B). This last protein resulted more 
abundant with respect to C1-INH-HAE group too (Fig.27C). Differences 
between these two groups were observed also for lysozyme (LYSC) and 
angiopoietin-1 (ANGP1), which showed higher levels in FXII-HAE group 
(Fig.27C). In FXII-HAE, S100A8 protein (S10A8), was increased with respect to 
the other two angioedema groups (Fig.27B-C). Similarly to C1-INH-HAE group, 
also in InH-AAE higher levels of salivary cystatin SN with respect to FXII-HAE 
group were observed (Fig.27B), while the signal recognition particle 68 kDa 
(SRP68) was increased with respect to both C1-INH-HAE (Fig.27A) and FXII-
HAE (Fig.27B) groups. 
Prediction of the proteases acting in saliva by the characterization of the 
salivary peptidome in the different groups 
The acidic soluble fraction of saliva from a subgroup of 10 patients (3 C1-INH-
HAE in basal phase, 1 in acute state and 1 in both cases; 2 FXII-HAE in basal 
condition, 1 in acute phase and 1 in both situations, and 1 Inh-AAE in basal 
phase) and 12 healthy controls were selected among the whole number of 
samples under study. The low-molecular-weight fraction (MW < 50 kDa) of 
each sample was analyzed in duplicate by top-down nano-HPLC-ESI-MS and 
MS/MS experiments. A total of 360 peptides, of which 246 different, were 
identified with confidence into the three angioedema groups and the control 
group, and their distribution can be observed in Fig.28. Only two peptides were 
common to all groups, belonging to proteins involved in the interaction with 
cytoskeletal structures, while no specific peptides were shared among the three 
angioedema groups with respect to controls. Thus, most of the identified 
peptides were exclusive for each group: 69 for C1-INH-HAE, 56 for FXII-HAE, 7 
for InH-AAE and 89 for controls.  
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Fig.28 Venn diagram representing the distribution of identified different 
peptides per group (C1-INH-HAE, red; FXII-HAE, blue; InH-AAE, green; and 
controls, orange). 
The list of the characterized peptides in each group was used to perform the in 
silico prediction of the proteases responsible for the naturally occurring 
peptidome, and thus to evidence possible differences among the three 
angioedema patient groups and the healthy controls. Fig.29-31 shows the 
percentage of peptides generated by the activity of different proteolytic 
enzymes predicted by Proteasix. From Fig.29 it is evident that different 
cathepsins (CTSB, CTSL1 and CTSS), several matrix metalloproteinases (MMPs) 
and the signal peptidase complex catalytic subunit (SEC11C) showed higher 
proteolytic activity in all the angioedema groups with respect to the healthy 
controls. On the other hand, the activity of meprin A (MEP1A and MEP1B) 
resulted higher in controls. However, it should be outlined that the robustness 
of these data is limited due to the small number of samples analysed, i.e. only 
one in the case of InH-AAE group. Moreover, the Proteasix software was 
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employed to evidence possible different proteolytic activity in saliva collected 
from C1-INH-HAE (Fig.30) and FXII-HAE (Fig.31) patients during the basal 
phase of the disease and the acute attack. The results highlighted increased 
proteolytic activities for different proteases in salivary samples collected during 
an acute attack as compared to both the basal phase and the control samples. 
Among them, matrix metalloproteinases (mainly MMP9) showed the most 
evident differences in both C1-INH-HAE (Fig.30) and FXII-HAE (Fig.31) 
groups. The disintegrin and metalloproteinase domain-containing protein 17 
(ADAM17) showed higher activity in acute samples of both angioedema groups 
with respect to basal samples and controls (Fig.30 and Fig.31). Conversely, 
inferior activity of MEP1A and kallikreins (KLK6 and KLK4 in C1-INH-HAE 
and FXII-HAE groups, respectively) was observed in patients, especially in 
their acute phase samples, as shown in Fig.30 and Fig.31). In FXII-HAE group, 
cathepsins D (CATD) and granzyme B (GZMB) displayed a decreased 
proteolytic action (Fig.31). 
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Fig.29 Percentage of peptides generated by the proteolytic activity of proteases predicted by Proteasix in the three groups of patients 
(C1-INH-HAE, red; FXII-HAE, light blue; Inh-AAE, green) and in the control group (yellow). 
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Fig.30 Percentage of peptides generated by the proteolytic activity of several proteases predicted by Proteasix in C1-INH-HAE basal 
phase (red), acute phase (brown) and control group (yellow). 
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Fig.31 Percentage of peptides generated by the proteolytic activity of several proteases predicted by Proteasix in C1-INH-HAE basal 
phase (light blue), acute phase (blue) and control group (yellow).
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Discussion 
 Wilson’s disease 
One relevant result obtained by Wilson’s disease saliva investigation concerns 
the in vivo characterization of several oxidized derivatives of S100A8, and 
S100A9. The two proteins showed different patterns of oxidation, in particular 
at the cysteine residue 42. In fact, while S100A8 was detected with C42 both 
reduced and oxidized, S100A9(L) was never detected in the reduced form. 
Moreover, S100A8 showed a major proneness with respect to S100A9(L) to the 
irreversible cysteine oxidation, and sulfonic or sulfinic acid were its main 
oxidized derivatives. On the other hand, S100A9 was detected principally 
glutathionylated and in a minor extent cysteinylated or in the dimeric form. 
S100A8 and S100A9 are the most abundant neutrophil proteins (about 45% of 
cytosolic proteins), constitutively expressed also by myeloid cells, platelets, and 
osteoclasts (Edgeworth, 1991; Goyette, 2011) and strongly induced in several 
cell types (i.e. macrophages, monocytes, keratinocytes, fibroblasts) during acute 
and chronic inflammatory status and in oxidative stress conditions (Goyette, 
2011; Carlsson, 2005). Interestingly, it has been reported that following liver 
damages, upregulated S100A8 and S100A9 induce neutrophils mobilization 
(Moles, 2014; Wiechert, 2012). In activated granulocytes and macrophages, 
S100A8 and S100A9 are involved in the activation of NADPH oxidase 2 
(Schenten, 2011; Doussiere, 2002), and thus contribute to the generation of 
reactive oxygen/nitrogen/chlorine species (ROS/RNS/RCS) with a subsequent 
progression and exacerbation of the inflammatory status. In addition to excess 
of unbound copper, different factors can be responsible for the redox unbalance 
in Wilson’s disease. In fact, Hussain et al. observed an increased expression of 
the inducible nitric oxide synthase (iNOS) (Hussain, 2000), while Ogihara et al. 
demonstrated a decreased level of plasma antioxidants (Ogihara, 1995). 
Furthermore, the decreased concentration of serum peroxiredoxin 2 isoform b 
was demonstrated in asymptomatic, early-stage patients (Park, 2009). Thus, the 
oxidative stress condition occurring in Wilson’s disease could be at the basis of 
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the high concentration of S100A8 and S100A9 proteoforms observed in our 
patients, and the up regulation of S100A8 should be responsible for the high 
levels of its oxidized forms, which however did not differ in percentage 
between patients and healthy controls. S100A8 in the form of sulfonic, or 
sulfinic acid, or oxidized at M1, M78 and W54 residues, has been already 
observed in vitro, by treating recombinant S100A8 with HOCl, as well as in vivo 
in human asthmatic sputum (Gomes, 2013), while the contemporaneous 
oxidation of C42 and the methionine residues has not been previously 
observed. The present study not only highlighted that more oxidative 
modifications can co-occur in S100A8, but also showed that the hyper-oxidized 
derivatives represented the major proteoforms of S100A8 in saliva of both 
patients and controls. Cysteine oxidation to sulfinic and sulfonic acid is 
generally considered an irreversible modification, which damages the protein. 
However, the enzymatic reversion of the sulfinic acid to the thiol form has been 
also observed (Biteau, 2003; Budanov, 2004). Reversible cysteine oxidation, such 
as glutathionylation, cysteinylation, and dimerization, can be involved in a 
variety of redox signaling/regulation events, and in the protection of critical 
cysteines from irreversible oxidative damages (Martínez-Ruiz, 2011; Hill, 2012; 
Lindahl, 2011). For instance, it has been reported that reversible cysteine 
oxidation of S100A8 and S100A9 can modulate their activity switching it from 
pro- to anti-inflammatory (Goyette, 2011; Gomes, 2013; Sroussi, 2012). In a 
previous study, it has been demonstrated in vitro that both S100A9 and S100A8 
can undergo glutathionylation via GSSG or GSNO intermediates, but only 
S100A9-SSG was detected in vivo in activated neutrophils (Lim, 2010). Thus, this 
is the first study which detected S100A8-SSG in vivo. Glutathionylation of 
S100A9 alters its capacity to form complexes with S100A8 (calprotectin), to bind 
endothelial cells, and limits neutrophil migration in inflammatory lesions. It has 
been suggested that this modification protects the protein from its oxidation to 
higher oligomers (Lim, 2010). The great sensitivity to oxidation of S100A8 and 
S100A9 is in agreement with the detection in saliva of Wilson’s disease patients 
of disulfide-linked homo-S100A9(L) and hetero-S100A8/A9(L) dimers. The 
S100A9(L)-SSdimer was previously detected in the activated neutrophils (Lim, 
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2010), and similar modifications of human S100A8, and murin S100A8 and A9 
were observed in vitro in the presence of HOCl, Cu2+ and/or H2O2 at low 
concentration (Kumar, 2001; Harrison, 1999). It has been reported that S100A8 
disulfide-linked dimers do not exhibit chemotactic action (Lim, 2009).  
AVAD and ASVD peptides were found at high concentration in almost all 
patients, while in 11/32 controls they were undetected. pIgR, a type I 
transmembrane glycoprotein playing the main role in the adaptive immune 
response on mucosal surfaces (Asano, 2011; Kaetzel, 2005), transports polymeric 
IgA across mucosal epithelial cells. It is upregulated by pro-inflammatory 
cytokines, hormones and microbial factors, through a signaling pathway 
involving toll-like receptors 3 and 4 (Kaetzel, 2005). A proteolytic cleavage 
occurring in the glycosylated extracellular portion of pIgR generates the 
secretory component (19-603 residues), which has been detected also in human 
saliva (Ramachandran, 2006). The cleavage occurs by action of unknown 
proteases, probably released by activated neutrophils (Kaetzel, 2005), and the 
highly conserved sequence 602-613 (PRLFAEEKAVAD) is believed to be the 
cleavage signal (Asano, 2011). The AVAD peptide originates by a cleavage 
occurring in this region at the level of K609, and the ASVD peptide derives 
from AVAD by the trypsin-like cleavage at R622. The cleavage releasing the C-
terminal glycine from both fragments could be made by several proteases, 
including cathepsins and matrix metallopeptidases. AVAD and ASVD peptides 
do not derive from the secretory component, and have a sequence partially 
overlapped to the transmembrane portion (639-661) of pIgR. Thus, they should 
originate by degradation of pIgR after its release from disrupted cell 
membranes. The increased levels of the AVAD and ASVD observed in our 
patients may be a consequence of an increased disruption of cell membranes, 
due to the high production of ROS characteristic of the pathology. However, it 
cannot be excluded that pIgR itself may be increased in Wilson’s disease 
patients, even though conflicting data about pIgR levels and liver diseases have 
been reported. For instance, high levels of pIgR have been associated to the 
invasion and metastasis of the hepatocellular carcinoma (Ai, 2011), while a 
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down regulation of pIgR in intestinal mucosa of animal models subsequent to 
acute liver necrosis has been observed (Fu, 2012). 
Wilson’s disease saliva was characterized by the higher concentration of α-
defensin 4 and α-defensin 2 with respect to controls. Unexpectedly, none 
variation of α-defensin 1 and 3 levels was observed, even if α-defensin 2 derives 
from their proteolytic cleavage (Valore, 1992). Besides antimicrobial activity, α-
defensins can modulate the inflammatory responses through regulation of 
cytokine production (Chaly, 2000; Lehrer, 2012). The property of corticostatin to 
inhibit cortisol production (Singh, 1988) is intriguing, since it has been 
demonstrated that in humans and in other mammals glucocorticoids induce the 
metallothioneins, which are important intracellular copper storages (Gedamu, 
1993; Miles, 2000). High levels of α-defensin 4, therefore, can indirectly down-
regulate the metallothioneins by contributing to increase the free copper, a 
feature not negligible in Wilson’s disease. From this point of view, it could be 
interesting to test metallothionein levels in a future study. 
 SAPHO syndrome 
SAPHO patients were characterized by low salivary levels of acidic PRPs. It is 
recognized that these proteins play an important role in the homeostasis of the 
calcium phosphate in the oral cavity, in the creation of a protective environment 
for the teeth, and in the modulation of the bacteria adhesion to the oral surfaces 
(Bennick, 1983b). Moreover, it has been shown that PRPs are cleaved by exo- 
and endo-proteases generating several small peptides (Messana, 2008b; Hardt, 
2005a; Sun, 2009; Helmerhorst, 2009) and it is interesting to outline the detection 
of fragments containing the GGRPQ C-terminal sequence among them 
(Helmerhorst, 2009; Drobni, 2006). Indeed, Huang et al. demonstrated that the 
selective binding of the GPPPQGGRPQ peptide inhibits colonization and 
growth of P. acnes, suggesting that these salivary peptides can participate to the 
innate immune system through the inhibition of specific microorganisms 
(Huang, 2008). Interestingly, GPPPQGGRPQ peptide matches with the 148-157 
sequence of PRP-1 and with the 26-35 sequence of the P-C peptide. Therefore, 
the lower concentration of PRP-1, P-C peptide, and PRP-3 (generated by PRP-1 
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proteolysis before secretion) in SAPHO patients may result in a reduced 
abundance of the active fragment GPPPQGGRPQ and an impaired resistance to 
colonization of P. acnes, which has been variably associated with SAPHO 
syndrome (Hayem, 2013). The isolation of P. acnes in SAPHO subjects has been 
linked to the hypothesis of this syndrome being triggered by a low-virulence 
pathogen in the initial phase,  then perpetuated by a subsequent inflammatory 
process (Hayem, 2007).  
Also salivary cystatins can suppress some viral infections (Ruzindana-
Umunyana, 2001; Gu, 1995) and cystatin SN plays a key role in controlling the 
proteolytic activity of the parasite Trypanosoma cruzi (Baron, 1999). It exhibits 
antifungal activity against Candida albicans, and candidiasis onset in 
autoimmune polyendocrine syndrome type 1 has been correlated with cystatin 
SN deficiency (Lindh, 2013). The low abundance of cystatin S1 and SN in 
SAPHO patients, demonstrated in the present study, may reflect in a reduced 
protection against microorganism infections. SAPHO patients with a shorter 
disease duration showed higher levels of cystatin SN than those with a longer 
disease duration, suggesting that cystatin SN production might decrease over 
time, during the chronic course of the disease. 
Another class of salivary proteins, playing a protective role in the mouth, is 
represented by histatins, which show inhibitory effect on several oral bacteria 
(White, 2009). Moreover, histatin-derived peptides have been demonstrated to 
be active against various microbes, such as Propionibacterium acnes (Oppenheim, 
1999). On the basis of the present data we may also speculate that histatins 
could play a role in the down-regulation of pro-inflammatory mediator 
production in SAPHO syndrome, characterized by increased concentrations of 
IL-8, IL-18, and TNF and enhanced TH-17 lymphocyte response (Hurtado-
Nedelec, 2008; Borgwardt, 2014). Indeed, histatin 3 has been observed to bind 
the heat shock cognate protein 70 (HSC70), blocking its interaction with the toll-
like receptors TLR2 and TLR4, and thus suppressing the production of 
cytokines IL-6 and IL-8 in gingival fibroblasts (Firinu, 2014a). The same 
cytokine suppression was also demonstrated for histatin 5, both in gingival 
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fibroblasts and in dendritic cells stimulated by P. gingivalis (Imamura, 2014; 
Imatani, 2000). 
The anti-inflammatory role of the histatins is also supported by the negative 
correlation found between the level of histatin 3 and ESR, the latter being a 
marker of inflammation. However, a positive correlation between salivary 
histatins and the serum CRP level, which was within the normal range in most 
of the SAPHO patients, was observed in this study. This result, is apparently in 
contrast with the anti-inflammatory role of histatins previously discussed, 
highlighting that further investigations are necessary to clarify whether and 
through which mechanisms histatins could be involved in the inflammatory 
pathways.  
CRP negatively correlated also with salivary S100A12. This negative correlation 
is in disagreement with the results reported by Pradeep et al. demonstrating 
that S100A12 positively correlated with CRP in gingival crevicular fluid and 
serum from patients with chronic periodontitis and type II diabetes (Pradeep, 
2014). However, the high abundance of S100A12 in SAPHO patients suggests a 
probable involvement of this protein in the inflammatory status typical of the 
disease. Antimicrobial and antifungal activities have been attributed to S100A12 
(Cole, 2001), it has been associated with chronic inflammatory conditions (Foell, 
2003a) such as cystic fibrosis (Lorenz, 2008), rheumatoid arthritis (Foell, 2003b), 
psoriasis (Foell, 2003b), and autoinflammatory diseases (Kessel, 2013). In 
particular, S100A12 has been found up-regulated in inflamed synovial tissue of 
patients affected by rheumatoid and psoriatic arthritis (Lorenz, 2008), and in 
saliva of HIV-1 positive patients with dysregulation of neutrophil response 
(Zhang, 2013). Interestingly, S100A12 has been shown to be a sensitive 
parameter to detect subclinical inflammation in familial Mediterranean fever 
(Kallinich, 2010). Its inflammatory properties are related to the chemoattractant 
capacity for monocytes and mast cells (Yan, 2008), to the ability to operate as a 
Damage Associated Molecular Pattern (DAMP) molecule (Foell, 2007), and to 
induce NFκB mediated expression of pro-inflammatory cytokines IL-1β, IL-18, 
IL-6 and TNF-α (Hofmann, 1999). The binding of S100A12 to TLR-4 and RAGE 
receptors on monocytes and granulocytes has been demonstrated to amplify 
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and perpetuate inflammation (Schmidt, 2001). The antagonization of IL-1β or 
TNF-α induced by these events represents an effective treatment for SAPHO 
syndrome (Firinu, 2014b). 
 Hereditary angioedema 
Increased levels of cystatin B, in particular of its S-glutathionylated derivative, 
were observed in the acidic soluble fraction of saliva from C1-INH-HAE and 
InH-AAE patients. This protein belongs to the cystatin family, inhibitors of 
cysteine proteases, mostly by interacting with the plant derived papain and the 
mammalian cathepsins B, L, S and H (Abrahamson, 1986; Turk, 1991). Cystatin 
B, that prevents the activity of cathepsin L (Ceru, 2010), shows mainly an 
intracellular localization (Abrahamson, 1986; Maher, 2014a) but it has been also 
detected in various body fluids and associated with neurodegenerative 
diseases, cancer and inflammation. For example, Cystatin B gene mutations 
have been reported to be responsible for the progressive myoclonus epilepsy of 
the Unverricht-Lunfborg type (EPM1), a degenerative disease of the central 
nervous system (Pennacchio, 1996; Lalioti, 1997; Bespalova, 1997; Joensuu, 
2007), high levels of the protein were observed in different malignant tumors 
(Feldman, 2009; Zhang, 2011), and in activated macrophages (Maher, 2014b; 
Kopitar-Jerala, 2015). In immune cells, cystatins have been reported to 
participate in the release of nitric oxide, phagocytosis, and expression of 
cytokines (Kopitar-Jerala, 2006; Maher, 2014a, Kopitar-Jerala, 2015), although its 
role is debatable. In fact, higher expression of the inducible nitric oxide synthase 
together with increased amounts of NO were observed in IFN-γ and LPS-
activated cystatin B-deficient bone marrow-derived macrophages by the 
Kopitar-Jerala group (Kopitar-Jerala, 2015). Conversely, various studies 
demonstrated the ability of cystatin B and others members of cystatin families 2 
and 3 (chicken and filarial cystatins, rat T-kininogen) to stimulate, in a 
concentration-dependent manner, the release of NO from IFN-γ activated 
murine macrophages (Verdot, 1996; Hartmann, 2002). Furthermore, it was 
demonstrated that the high and rapid NO production by the inducible NO 
synthase was not related to the inhibitory properties of cystatins (Verdot, 1996; 
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Hartmann, 2002). The role of cystatin B in NO production is interesting as this 
molecule not only directly acts against the pathogen infection (James, 1995), but 
also induces vasodilatation and inhibits platelet aggregation (Riddell, 1999). 
Thus, it might be hypothesized that the increased levels of salivary cystatin B in 
our patients could be connected to an enhanced NO release, participating, 
together with bradykinin, to the vasodilatation and the higher vascular 
permeability responsible for hereditary angioedema.  
Furthermore, recent studies demonstrated that the C1-INH protein plays anti-
inflammatory functions, not related to its protease activity, preventing the 
binding of LPS to macrophages and, consequently, preventing their activation 
(Liu, 2003). Therefore, the reduced activity of the C1 inhibitor in C1-INH 
patients may results in an impaired macrophage activation, with the production 
of higher levels of cystatin B and in the increased stimulation of nitric oxide 
formation.  
The high proteolytic activity of several matrix metalloproteinases observed in 
all the groups of angioedema patients, which increases during an acute attack of 
edema, is in agreement with the strong degradation of the extracellular matrix 
proteins (i.e. collagen, elastin, gelatin and fibronectin), which is a typical feature 
of inflammation, enhancing leukocyte migration and the vascular leak 
responsible for edema formation. Active matrix metalloproteinases are unstable 
and can cleave and inactivate themselves. This autolytic process is modulated 
and prevented by the tissue inhibitors of matrix metalloproteinases, TIMPs 
(Ochieng, 2010). Curiously, different cystatin members are able to stabilize 
metalloproteinases, protecting them from their own inactivation, without 
interfere with their enzymatic activity against their natural substrates (Ray, 
2003; Ochieng, 2010). Therefore, the higher levels of cystatin B measured in our 
patients may contribute to MMPs stability which can reflect in their increased 
proteolytic activity observed in saliva samples of angioedema patients.  
Conversely, the higher activity of cathepsins in saliva of our angioedema 
patients, apparently contrasts with the increased levels of cystatin B, which 
belong to the family of their classical inhibitors.  
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Among the proteins characterized in the acidic insoluble fraction and showing 
significant different levels in the three angioedema groups, several  proteins 
involved in inflammation are represented. Cystatin A, higher in C1-INH-HAE 
than FXII-HAE group, is involved in the skin development and cellular 
proliferation. It has been observed in psoriatic plaques of the psoriasis vulgaris, 
an inflammatory disease of the skin (Bowcock, 2001), and polymorphisms of its 
gene have been associated with atopic dermatitis (Cork, 2006; Vasilopoulos, 
2007) and exfoliative ichthyosis (Blaydon, 2011). On the other hand, S100A8 
protein, strongly expressed in activated macrophages, monocytes, keratinocytes 
and fibroblasts during inflammation and oxidative stress (Goyette, 2011; 
Carlsson, 2005), was over-expressed in FXII-HAE patients. Other proteins, 
which showed different levels among angioedema groups, play anti-microbial 
activities, i.e. cystatin SN (higher in C1-INH-HAE and InH-AAE groups), 
lactotransferrin (increased in C1-INH-HAE with respect to the other patients) 
and lysozyme (more abundant in FXII-HAE group). The bioinformatic analysis 
performed on proteins and peptides identified in the acidic insoluble fractions 
of saliva is in agreement with the significant activation of pathways involved in 
the organism response against microorganisms, in the development of the skin 
and in the extracellular matrix organization. Moreover, it is interesting to 
observe the high S-nitrosylation activity associated to the glyceraldehyde-3-
phosphate dehydrogenase (GADPH), which could be connected with a massive 
production of NO. 
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Conclusions 
Wilson’s disease, SAPHO syndrome and hereditary angioedema are 
characterized by a wide spectrum of clinical manifestations, involving different 
organs and apparatus, which can be extremely dangerous and even lead to the 
death of the patient if not immediately recognized and treated. The absence of a 
confident method of diagnosis and the overlap of some clinical symptoms with 
other similar diseases, implicate difficulty in diagnosis, which represents a 
challenge for clinicians; thus, the characterization and validation of new 
disease-specific biomarkers urges. 
Saliva investigations interestingly demonstrated that proteomic and peptidomic 
variations could be related not only to oral but also to systemic disorders 
(Grigoriev, 2003; Sayer, 2004; Vitorino, 2006; Peluso, 2007; Ohshiro, 2007; 
Castagnola, 2008; Ito, 2008; Hu, 2008; Wu, 2009; Rao, 2009; Cabras, 2010; Cabras, 
2013; Caseiro, 2013), suggesting a possible employment of this body fluid for 
diagnostic and prognostic purposes (Castagnola, 2011b; Caseiro, 2013).  
Indeed, the results obtained in this study devoted to the characterization of the 
salivary proteome of Wilson’s disease, SAPHO syndrome and Hereditary 
angioedema patients highlighted that saliva composition is affected by the 
pathology and reflects the typical features of the disorders. In particular, in 
Wilson’s disease patients the salivary proteome, characterized by high levels of 
S100A8, S100A9 and their oxidized isoforms, reflected the intense oxidative 
stress and the activation of the inflammatory processes caused by the 
accumulation of copper in the organism. In addition, the high abundance of 
corticostatin suggests new mechanisms involved in the augmented levels of free 
copper. Of particular interest is the increased concentration of pIgR fragments, 
which deserves further evaluation as possible index of hepatic damage. The 
salivary proteome of patients affected by SAPHO syndrome evidenced a 
significant reduction of cystatins, histatins, and aPRPs, which may be related to 
a reduced ability to contrast colonization from bacteria, such as P. acnes, often 
associated as possible exogenous trigger of the disease. Moreover, the high 
abundance of S100A12 in saliva of SAPHO patients encourage further studies to 
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confirm its association with the disease and to evaluate its possible application 
as salivary biomarker. The activation of the immune system is also reflected in 
saliva from all angioedema patients, by the increased abundance of several 
peptides generated by metalloproteinases. The high level of cystatin B in C1-
INH-HAE patients, could be related to the macrophage activation caused by a 
reduced C1-INH activity, and the similar cystatin B levels observed in C1-INH-
HAE and InH-AAE with respect to both FXII-HAE and control groups may 
suggest that the acquired angioedema involves mechanisms of the immune 
system more similar to the angioedema caused by SERPING1 mutations than 
angioedema related to FXII gene mutations. 
Eventhough the small number of the subjects under study, due to the rarity of 
the investigated pathologies, represents a limitation for the statistical power of 
the results, it should be outlined that the proteomic and peptidomic 
modifications with respect to controls observed in saliva of patients were 
distinctive for each disease, also reflecting the typical derangement of the 
disorder. Further studies on a larger cohort of patients to confirm the variations 
of the salivary proteome/peptidome observed and their disease-specificity as 
well as validation of the results by orthogonal methods will allow in the future 
to establish the actual applicability and the diagnostic power of a salivary test 
for these pathologies. 
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